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Numerous epidemiological studies show a strong association between low birth 
weight and later life hypertension and metabolic disease. Excessive in utero exposure 
to glucocorticoids (‘stress hormones’) has been hypothesized to be important in such 
developmental ‘programming’, acting via crucial physiological, gene expression or 
structural changes in the developing fetus. Normally, the fetus is protected from the 
high levels of maternal glucocorticoids by an enzymic placental barrier, 11 beta-
hydroxysteroid dehydrogenase type 2 (11β-HSD2). In the placenta, 11β-HSD2 
efficiently converts active maternal glucocorticoids (cortisol in humans; 
corticosterone in rodents) to physiologically inactive 11-keto forms. In previous 
studies in rats, maternal administration of dexamethasone, a synthetic glucocorticoid 
which is minimally metabolized by 11β-HSD2, or carbenoxolone, a potent inhibitor 
of 11 β-hydroxysteroid dehydrogenase, increased glucocorticoid load to the fetus. 
This resulted in lower offspring birthweight and later life hypertension and 
hyperglycemia — important components of the metabolic syndrome. These 
programming effects were seen when dexamethasone was administered selectively 
during the third week of gestation. 
We have used this well-validated model of programming to dissect the molecular 
mechanisms that mediate the programming of hypertension.  
 
In accord with previous observations, administration of dexamethasone 
(100µg/kg/day) to pregnant rats during the last week of pregnancy significantly 
 
x 
reduced offspring birthweight by 10%. Moreover, the 9 month-old adult offspring 
had systolic hypertension (9% rise) accompanied by significant hypokalemia (10% 
fall K
+
). The coexistence of hypertension and hypokalemia suggested that prenatal 
overexposure to dexamethasone might increase mineralocorticoid activity in the 
kidney. Intriguingly, although offspring of dexamethasone-treated dams had 46% 
lower plasma renin concentrations (consistent with intravascular fluid volume 
expansion), 24-hour total urinary aldosterone levels were significantly reduced 
compared to controls (reduction of 56%).  
 
Maternal dexamethasone treatment was associated with a permanent decrease in 11β-
HSD2 mRNA and activity in the kidney of the offspring (45% and 36% 
respectively). 11β-HSD2 plays an important role in regulation of renal sodium 
reabsorption (and thereby blood pressure) by acting as a pre-receptor barrier to MR 
access, preventing glucocorticoids from activating MR in the distal nephron. Thus, 
the decrease in renal 11β-HSD2 activity would allow greater endogenous 
glucocorticoids to activate MR, likely accounting for the low-renin, low-aldosterone 
hypokalemic hypertensive phenotype observed in these offspring.  
 
Other components of mineralocorticoid or glucocorticoid signaling pathways, 
including mineralocorticoid receptor (MR), glucocorticoid receptor (GR) and 11-beta 
hydroxysteroid dehydrogenase type 1 (11β-HSD1) were not altered in the offspring 
kidney by prenatal glucocorticoid exposure. Dexamethasone-programmed offspring 
also showed exaggerated mineralocorticoid activity with increased kalliuresis in 
response to exogenously administered corticosterone, suggesting that the decrease in 
 
xi 
renal 11β-HSD2 is functionally important. In this respect, our rat model resembles 
the syndrome of apparent mineralocorticoid excess where reduced 11β-HSD2 allows 
illicit activation of MR by glucocorticoids, resulting in excessive sodium 
reabsorption, hypertension and hypokalemia. 
  
We also studied the effects of maternal dexamethasone on offspring erythropoietin 
expression in the kidney. This followed from previous observations that identified 
the hepatocyte nuclear factor 4 alpha (HNF4α) as a key gene up-regulated in 
dexamethasone-programmed offspring liver, where it might be involved in mediating 
hyperglycemia. HNF4α is also expressed in the kidney. The role of HNF4α in the 
kidney is not fully understood, but has been implicated in regulation of 
erythropoietin synthesis. 
 
As in the liver, prenatal exposure to dexamethasone caused a significant increase 
(64% increase) in renal HNF4α expression. The increase in renal HNF4α mRNA was 
observed early (in one week old offspring) and persisted into adulthood. This was 
associated with significantly elevated levels of erythropoietin in circulation (110% 
increase). Moreover, animals that were exposed to prenatal dexamethasone had 
significantly increased red blood cell mass (7% increase), presumably as a result of 
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Fig 1-1 Schematic representation of action of glucocorticoid hormones 
Fig 1-2 The hypothalamic-pituitary-adrenal (HPA) axis  
Fig 1-3 Determinants of glucocorticoid action 
Fig 1-4 11β-HSD2 as placental barrier 





Fig 3-1           Effect of dexamethasone on offspring body weight at 9 months  
  
Fig 3-2 There was a significant increase in the systolic blood pressure in the 
dexamethasone -programmed animals when compared to controls 
 
Fig 3-3 Effect of prenatal dexamethasone on blood pressure at 2 months 
  
Fig 3-4 Effect of prenatal dexamethasone on 2 month old offspring blood 







Fig 4-1 Effect of prenatal dexamethasone on renal mRNA expression of 11β-
HSD1, 11β-HSD2 and renal 11β-HSD2 enzyme activity. 
 
Fig 4-2 Effect of prenatal dexamethasone on the renal mRNA expression of 
GR and MR 
 
Fig 4-3 Effect of prenatal dexamethasone on the renal mRNA expression of 
ENaC (α, β, γ).   
 
Fig 4-4 Effect of prenatal dexamethasone on the renal mRNA expression of 
Sgk1 
  
Fig 4-5 Effect of prenatal dexamethasone on renal 11β-HSD2 distribution 
 












Fig 5-1 Effect of prenatal dexamethasone on EPO mRNA expression in 1 
week old and 9 months old offspring 
 
Fig 5-2 Effect of prenatal dexamethasone on plasma EPO concentration in 9 
months old offspring  
 
Fig 5-3 Effect of prenatal dexamethasone on hepatic EPO mRNA expression 
at E21 
 
Fig 5-4 Effect of prenatal dexamethasone on renal HNF4α mRNA expression  
 
Fig 5-5 The effect of prenatal dexamethasone on transcriptional regulators of 





Fig 6-1 Proposed hypothesis and mechanisms  
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Table 3-6  Effect of prenatal dexamethasone on salt-sensitivity in 2 month old 
offspring  
 
Table 3-7 Effect of prenatal dexamethasone on plasma concentrations of sodium 
at 2 months after 1 week of high salt diet 
 
Table 3-8  Effect of prenatal dexamethasone on plasma concentrations of 
potassium at 2 months after 1 week of high salt diet 
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Table 4-1 Effect of exogenous cortisol on urinary sodium/potassium ratio in 9 
months old offspring 
 
Table 4-2  Effect of exogenous cortisol on urinary sodium concentration in 9 
month old offspring 
 
Table 4-3  Effect of exogenous cortisol on urinary potassium concentration in 9 

























































A series of worldwide epidemiological studies starting in the mid 1980s, have 
provided evidence for the strong association between disturbances in fetal 
development, as represented by low birth weight and cardiovascular mortality in 
adult life. The numerous accompanying animal and human studies that have 
followed since, have attempted to understand the myriad molecular, cellular, 
metabolic, neuroendocrine and physiological basis for understanding how adverse 
environmental effects, acting on the developing fetus, result in permanent alterations 
of the developmental pattern of cellular proliferation and differentiation in key tissue 
and organ systems, with resultant pathological consequences observed in adult life. 
(McMillen and Robinson 2005).  
 
Our laboratory in Edinburgh, led by Professor Jonathan Seckl, as well as other 
investigators internationally,  have hypothesized that excessive fetal glucocorticoid 
exposure may be an important mediator of low birth weight and later life chronic 








THE DEVELOPMENTAL ORIGINS OF DISEASE 
 
That early life events play an important role in the later life phenotype is now well 
recognized. This concept is not without precedence; for instance, well over a century 
before, Weisman demonstrated that the early environmental temperature plays a 
critical role in phenotypic development in butterflies. Thus butterflies that hatched in 
summer were colored differently from those that hatched in winter, and this season-
dependent coloration could be mimicked by incubating larvae at different 
temperatures. 
 
Traditionally, cardiovascular disease and diabetes have been linked to adult lifestyle 
factors like diet, smoking and obesity. For example, in recent years, Willett, in 1994, 
noted that consumption of a diet high in fat, low in starch and fibre, appears to 
substantially increase the risk of cardiovascular mortality (Willett 1994). However, 
clinical epidemiological evidence suggests that prenatal experience may play an 
important role in the risk of development of subsequent cardiovascular and metabolic 
disease. Barker et al identified an association between the prevalence of 
cardiovascular disease among middle-aged men and low birth weight early in the 
1980s (Barker, 1994). Their work indicated that adverse factors experienced in early 
life resulted either in death, or adaptative changes that might have contributed to 
disease risk in later adult life (Barker, 1994). Such findings were verified through 
large follow-up studies of patient cohorts across the United Kingdom, thus providing 
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evidence of associations between low birth weight and subsequent adult risk of 
cardiovascular disease, hypertension and diabetes. Since then, he and his colleagues, 
as well as other investigators,  have demonstrated that low birth weight predicts the 
subsequent development of diseases like hypertension (Barker et al. 1990), ischemic 
heart disease , type 2 diabetes mellitus (Phillips et al. 1994), vascular dysfunction 
(Martyn et al. 1995), obesity (Yajnik 2000) and dyslipidemia (Barker et al. 1993c) in 
adult life (Barker et al. 2001).  However it should be noted that the relationship 
between the risk of developing these chronic diseases and low birth weight is a 
continuous and quantitative one: the lower the birth weight, the greater the risk of 
developing later life hypertension. Additionally, the influence of birth weight on later 
disease is independent of the commonly acknowledged lifestyle risk factors in 
adulthood, namely adult weight, social economic status, smoking, alcohol 
consumption and sedentary lifestyle. Indeed, the adult ‘lifestyle’ risk factors are 












Further studies have led to a re-evaluation of the early work, demonstrating that 
subtle deviations in the fetal growth pattern leading to disproportion at birth 
(thinness, large head circumference in proportion to body length, small abdominal 
circumference, relative larger placenta when compared to birth weight) are more 
significant predictors of later disease risk (Langley-Evans 2001, Yajnik et al. 1995). 
In fact, in a British population, a baby with low birth weight and a large placenta had 
a relative risk of hypertension in adulthood that is three times higher than a baby with 
normal birth weight and a normal- sized placenta (Barker et al. 1990). For each birth 
weight, both systolic and diastolic pressures rose with placental weight, and for each 
placental weight both pressures fell with increasing birth weight. The highest 
pressures were among people who had been small babies with large placentas and the 
lowest were among people who had been large babies with small placentas (Barker et 
al. 1990) 
 
Furthermore, the influence of early life on adult health is present in both developing 
countries, such as India (Yajnik et al. 1995, Krozowski et al. 1999, Stein et al. 1996) 
and Jamaica (Forrester et al. 1996), as well as the more developed countries like the 









To explain the association between low birthweight and adult type 2 diabetes, Hales 
and Barkers proposed that in suboptimal fetal environment, the fetus makes an 
adaptive response to maximize uptake and conservation of any available nutrient, 
thus optimizing the growth of key body organs at the expense of others, leading to a 
permanent altered postnatal metabolism designed to enhance offspring postnatal 
survival under conditions of poor nutrition.  (Hales and Barker 2001, Barker et al. 
1993b, Hales and Barker 1992).  This adaptation of the thrifty phenotype was 
thought to confer a survival advantage in these fetuses, arming them with the best 
ability to withstand any poor postnatal environment. It was proposed
 
that these 
adaptations only became detrimental when nutrition
 
was more abundant in the 
postnatal environment, than it had
 
been in the prenatal environment.  
 
This ability of the early environment to influence the phenotypic outcome of the 
adult individual is thought to reflect developmental plasticity, in which normal 
processes allow a range of phenotypes to develop from a single genotype (Gluckman 
et al. 2005a). The human fetus and infant can respond to unbalanced nutrition and 
other adverse influences by changing their developmental and growth trajectories 
(Gluckman et al. 2007, Gluckman and Hanson 2004). Plasticity may be responsible 
for the development of adaptive mechanisms that will ensure a successful survival 
later in life. (Bateson 2001, Bateson et al. 2004).  
 
Cues for plasticity operate particularly during early development; they may affect a 
single organ or system, but generally they induce integrated adjustments in the 
mature phenotype, a process that is thought to be dependent on prediction of the 
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mature environment and may be underpinned by non-genetic e.g. epigenetic 
mechanisms. Thus, an adverse intrauterine environment results in responses that alter 
the developmental trajectory in preparation for harsh postnatal conditions. In 
generating a varied range of phenotypes adapted to thrive in different environments, 
developmental plasticity will contribute to the perpetuation of the genotype.  
 
Unfortunately, developmental plasticity may also influence the eventual pathogenesis 
of chronic human disease by mismatch in the predicted versus actual postnatal 
environment. (Gluckman et al. 2008, Gluckman et al. 2005b, Gluckman et al. 2005d, 
Gluckman et al. 2005c, Gluckman et al. 2005a, Gluckman et al. 2007, Bateson et al. 
2004). Mismatch between the anticipated and the actual mature environment would 
have adverse consequences on organism, and the greater the mismatch, the greater 
the risk of development of chronic diseases like high blood pressure, obesity and 















PROSPECTIVE EPIDEMIOLOGICAL EVIDENCE FOR LINK BETWEEN 
LOW BIRTH WEIGHT AND LATER DISEASE: DUTCH HUNGER FAMINE 
AND THE LENINGRAD SIEGE 
 
The earliest epidemiological studies of fetal programming were retrospective studies 
focused on the association between birthweight and adult disease in geographically 
localized populations. Barker et al demonstrated a relationship between birthweight 
and adult diseases like hypertension, insulin resistance, vascular dysfunction, obesity 
and dyslipidemia. Barker and colleagues suggested that poor nutrition in pregnancy 
impairs fetal growth or promotes disproportionate fetal growth; leading to 
subsequent adaptations that promote survival in adverse conditions could lead to 
limited physiological function and disease in the long term. 
 
The significance of maternal nutrition, the effect of poor nutrition on birthweight and 
subsequent adulthood disease was addressed in studies of exposure to famine, most 
notably the Dutch Famine of 1944–1945, which provides a powerful quasi-
experimental prospective model to study the long-term consequences of maternal 
exposures in defined stages of gestation (Ravelli et al. 1998, Stein et al. 2006, Lumey 
et al. 1993, Ravelli, Stein and Susser 1976, Ravelli et al. 1999, Roseboom et al. 1999, 
Roseboom et al. 2001b, Roseboom et al. 2001a). The Dutch famine was at its worst 
for 5 months from December 1944 to April 1945, and this has provided data on the 
influence of maternal under-nutrition during different periods of gestation on later 
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offspring health (Morley 2006). For instance, data showed that the exposure to the 
Dutch famine (where average daily caloric intake was limited to 1680–3360 kJ) 
during late gestation was associated with increased adult obesity and glucose 
intolerance while famine exposure early in gestation resulted in hypertension (Stein 
et al. 2006). 
 
In contrast,  the one other study of adults exposed to famine during gestation, also 
during the second world war in Europe, conducted among survivors of the siege of 
Leningrad (now St. Petersburg) Russia, no association was observed between famine 
exposure and blood pressure levels at age 40 years (Stanner and Yudkin 2001). Data 
relating to the Leningrad siege, however, did not include birth weights, and the 
famine lasted much longer (almost 2 and a half years), so that most subjects would 
have been exposed throughout gestation and in infancy, and many mothers would 
have been exposed to famine before conception. As the nutritional status both before 
and after the famine periods in Leningrad was poor, the predictive adaptive responses 
may therefore have been appropriate for the postnatal environment experienced.  
 
On the other hand, nutrition following the Dutch famine was relatively plentiful and 
the subsequent adult nutritional environment was much better than that predicted by 
the predictive adaptive responses, with subsequent manifestation of disease. It has 
been thus suggested that an important difference between subjects exposed to the 
Dutch versus Leningrad famines may be that the former experienced improved 
nutrition postnatally whereas most of the latter did not (Morley 2006). 
 
9 
Epidemiological evidence have also unraveled one other important aspect about the 
perinatal environment’s effect on the risk of development of metabolic syndrome and 
cardiovascular disease: that impaired fetal growth followed by rapid catch-up in 
infancy might be an even stronger predictor of obesity, hypertension, non-insulin-
dependent diabetes and coronary artery disease ( Singhal A 2004, Langley-Evans 
2006).   
 
Data from other population-based studies suggest that growth restriction in utero is 
less detrimental to health in the long term when postnatal nutrition is compromised to 
a similar degree (Primatesta, Falaschetti and Poulter 2003). In keeping with the 
hypothesis of ‘catch-up growth’, babies that are born small but grow rapidly in the 
first months of life to eventually achieve normal centiles, have been identified as 
being at particularly risk of developing cardiovascular disease, and/or the metabolic 















FETAL PROGRAMMING MODELS 
 
To better understand the molecular mechanisms behind the epidemiological findings, 
animal models with shorter lifespan have been developed under controlled 
experimental conditions.  
 
In the literature, many such experimental “programming” models (such as maternal 
malnutrition and/or protein restriction, uterine artery ligation, excessive fetal 
exposure to glucocorticoids, among others,) have reliably and consistently 
recapitulated the epidemiological observation of low birth weight offspring and the 
development of cardiometabolic perturbations (such as higher blood pressures and 
hyperglycemia), allowing for the dissection of molecular mechanisms that could 
explain the link between low birth weight and later life disease. 
 
In essence,  this experimentally useful notion of “programming” encapsulates the 
idea that a  particular factor can act during a sensitive developmental period to 
reliably “program” consistent changes in the development and organization of 
specific tissues that are concurrently vulnerable, thus producing effects that persist 
throughout the adult life (Seckl 2004), which may then lead to a greater risk of 
chronic disease development. Due to different cells and tissues being sensitive at 
different times or different stages of development, the varying environmental stimuli 
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will exert distinct effects, depending on the nature of that stimulus as well as its 
timing (Seckl 2004). 
 
A number of factors may have programming effects, but most available and 
consistent evidence relates to maternal nutrition and hormones, but other agents may 
include toxins and drugs (Csaba 1986). Among hormones, sex steroids and 
glucocorticoids are thought to be particularly important. 
 
Perinatal programming by sex steroids is perhaps one of the best documented 
examples of programming. In many vertebrate species, male fetuses demonstrate a 
short burst of androgen secretion around the time of birth, which permanently 
programs steroid metabolising enzyme expression in the liver, as well as the size, 
connection and neurochemistry of specific hypothalamic nuclei, which ultimately 
affects sexual behaviour (Arai and Gorski 1968, Gustafsson et al. 1983).  For 
instance, the sexually dimorphic nucleus of the preoptic hypothalamic area is larger 
in male rats because testosterone inhibits apoptosis in this locus specifically between 
postnatal days 6 and 10, resulting in the male adult phenotype (Davis, Popper and 
Gorski 1996). Similarly, the programming effects of oestrogens  on the developing 
central nervous system is well-recognized (Simerly 2002).  Despite being exerted 
only during specific perinatal periods, the organizational effects of sex steroids 








PROGRAMMING BY GLUCOCORTICOIDS 
 
Glucocorticoid hormones play pivotal roles in both normal physiology and 
coordinating response to stress. In mammals, glucocorticoids regulate a variety of 
important cardiovascular, metabolic, immunological and other homoeostatic 
function. In particular, glucocorticoids play an important role in the regulation of 
blood pressure, glucose and stress. For instance, excessive glucocorticoid levels, 
resulting from either exogenous administration or endogenous overproduction (e.g. 
in Cushing’s syndrome), with subsequent development of diabetes, hypertension 
(Baid and Nieman 2004, Thomson et al. 2007, Howlett, Rees and Besser 1985) and 
depression (Chrousos and Kino 2007, Welberg, Seckl and Holmes 2000) 
 
Studies in our laboratory have used a well-validated animal model: the 
dexamethasone- programmed rat, whereby dexamethasone 100 mcg/kg is given 
during embryonic days 15 to 21 of maternal gestation in rats (third trimester). In this 
model, excessive fetal glucocorticoid (dexamethasone) exposure not only reduced 
offspring birthweight by about 10-14% consistently, but also predisposed adult 
offspring to higher blood pressures, glucose intolerance and hypercortisolism 
(Benediktsson et al. 1993, Lindsay et al. 1996, Nyirenda et al. 1998, Levitt 1996).  
 
Dexamethasone is a poor substrate for 11β-HSD2 in the placenta, which is an 
efficient enzymic barrier that metabolize maternal active glucocorticoids into 
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inactive glucocorticoids, thereby keeping glucocorticoid levels in the fetal circulation 
much lower than in the maternal circulation. In this experimental model, prenatal 
administration of dexamethasone reduces birth weight, presumably by increasing 
fetal glucocorticoid load and its catabolic actions (as detailed in the section on 
glucocorticoid physiology) especially during the phase of greatest fetal somatic 
growth during the third trimester. 
 
 Similar programming effects in the offspring were also observed in rodent models 
using carbenoxolone, a potent inhibitor of placenta 11β-HSD2, allowing increased 
endogenous maternal glucocorticoid to pass through the placental enzymic barrier 
unmetabolised and thereby increasing fetal glucocorticoid load. These effects of 
carbenoxolone are independent of changes in maternal blood pressure or electrolytes, 
but do require the presence of maternal glucocorticoids: the offspring of 
adrenalectomised pregnant rats are protected from carbenoxolone effects upon birth 
weight or adult physiology (Lindsay et al. 1996). 
 
 This model of glucocorticoid programming of the fetus, as well as work from other 
investigators, has led to the hypothesis that fetal overexposure to glucocorticoids 
might mediate the link between low birth weight and risk of cardiovascular and 
metabolic diseases in adulthood (Seckl 1994, Nyirenda et al. 1998).  Not 
surprisingly, prenatal glucocorticoids have been found to effect changes in 
corticosteroid biology, which in turn mediates the programming effects observed in 




For instance, in this model, GR was found to be upregulated in the periportal zone of 
the liver. This was associated with upregulation of PEPCK, a key gluconeogenic 
enzyme (known to be transcriptionally upregulated by GR) likely contributing to 
hyperglycemia observed (Nyirenda MJ et al 1998). Similarly, downregulation of GR 
in the hippocampus was observed leading to basal and stress hypercortisonemia 
(Levitt NS et al 1996), whereas upregulation of GR in the amygdala was associated 
with anxiety-like behaviour observed in the rat offspring (Welberg LAM et al 2001).  
Additionally, upregulation of hepatic 11β-HSD1, an important enzyme that amplifies 
local glucocorticoid action, has been observed in dexamethasone-programmed 
marmoset offspring that developed features of the metabolic syndrome (Nyirenda MJ 
et al 2009). 
 
In the next sections, pertinent aspects of glucocorticoid biology will be discussed, 
given the important role of glucocorticoids and placental 11β-HSD2 in the 














MOLECULAR MECHANISMS OF GLUCOCORTICOID ACTION 
 
Glucocorticoids are produced by the adrenal glands and pass through the plasma 
membrane into the cytoplasm in target organs where they bind to specific 
glucocorticoid receptor (GR), a 94 kDa protein which is a member of the nuclear 
receptor superfamily of ligand-activated transcription factors (Hollenberg et al. 1985, 
Yamamoto 1985, Muller and Renkawitz 1991). In certain tissues, glucocorticoids can 
bind to and activate the mineralocorticoid receptor (MR). Within the cytoplasm, GR 
is bound to HSPs (heat shock proteins). Upon hormone binding, activated GR 
dissociates from heat shock proteins and forms a homodimer. These then 
translocated to the nucleus and bind to specific DNA-responsive elements 
(glucocorticoid response elements) to affect target gene transcription (Gronemeyer 
1992, Beato, Herrlich and Schutz 1995). Glucocorticoids may also bind to receptors 
localized on the cell membrane and, through intracellular signaling pathways, 
mediate fast non-genomic action. 
 
The GR has at least two isoforms (GRα and GRβ). GRβ, a truncated form of GRα, is 
an inactive species of GR. The molecular weights of these receptor isoforms are 97 
and 94 kDa respectively. The GRα resides mainly in the cell cytoplasm and 
represents the classic GR which functions as a ligand-dependent transcription factor. 
The GRβ, however, does not bind glucocorticoid agonists and exerts a dominant 
negative effect upon the transcriptional activity of GRα (Chrousos 2004, Zhou and 
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Cidlowski 2005, Duma, Jewell and Cidlowski 2006, Kino et al. 2009, Oakley et al. 
1999).It has been postulated that the relative proportion of GRα and GRβ, not just 
total GR expression levels, might account for tissue-specific differences in GR 
activity.  
 
Glucocorticoid action is controlled and modulated at several levels. First, secretion of 
glucocorticoids from the adrenal cortex is controlled by the hypothalamic-pituitary-
adrenal (HPA) axis, via a classical negative feedback loop. Corticotrophin releasing 
hormone (CRH) synthesized in the neurons of the paraventricular nucleus (PVN) of 
the hypothalamus is released into the hypophyseal portal circulation. Corticotrophin 
releasing hormone stimulates adrenocorticotropic hormone (ACTH) synthesis and 
release from corticotroph cells of the anterior pituitary gland. In turn, 
adrenocorticotropic hormone stimulates production and release of glucocorticoids 
from the zona fasciculata-reticularis of the adrenal cortex. Glucocorticoids act on 
target organs throughout the body and provide negative feedback inhibition of CRH 
and ACTH in the hypothalamic-pituitary-adrenal (HPA) axis (Chrousos 1995). 
Additionally, HPA axis activity can also be modulated by higher centres, notably the 
hippocampus and amygdala (Feldman and Conforti 1980, Jacobson and Sapolsky 
1991). 
 
After secretion from the adrenal cortex, the binding of circulatory glucocorticoids to 
plasma proteins such as corticosteroid binding globulin (CBG) and albumin may 
affect the circulatory glucocorticoids in 2 ways: 
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1. By limiting the concentration of free glucocorticoids (which are biologically 
active) and  






Schematic representation of action of glucocorticoid hormones 
Mechanisms underlying the role of glucocorticoids in the early life programming of 




     CRH Corticotrophin releasing hormone 















Fig 1-3 Determinants of glucocorticoid action 
Legend 
GC Glucocorticoid    
IGC Inert form of Glucocorticoid 
GR Glucocorticoid Receptor 
CBG Corticosteroid Binding Globulin 
11β-HSD1 11 Beta Hydroxysteroid  
                  Dehydrogenase type 1 
11β-HSD2 11 Beta Hydroxysteroid  





At a cellular level, 2 important enzymes, 11β-hydroxysteroid dehydrogenase (11β-
HSD) enzymes type 1 and 2 regulate local glucocorticoid concentrations by either 
catalyzing activation or inactivation of glucocorticoids. For example, although 
glucocorticoids and mineralocorticoids bind with equal affinity to MR ex-vivo 
(Krozowski and Funder 1983), it is only mineralocorticoids which transactivate MR 
in aldosterone –target tissues in vivo. This is accomplished, as discussed below, by 
11β-HSD2, which co-localises with MR in the distal nephron, acting as an 
intracellular pre-receptor barrier, and selectively catalyses the rapid conversion of 
physiologically active glucocorticoids (cortisol in man, corticosterone in rats) into 
inactive 11-keto glucocorticoids  (cortisone and 11-dehydrocorticosterone 
respectively) (Edwards et al. 1988, Funder et al. 1988). Thus, only 














GLUCOCORTICOID ACTION DURING DEVELOPMENT 
 
GR is expressed in most fetal tissues from mid-gestation onwards (Schmid et al. 
1995, Cole et al. 1995b) and in the placenta (Sun, Yang and Challis 1997), while 
expression of MR has a more limited tissue distribution and is present only at later 
gestational stages, at least in rodents (Brown et al. 1996). Glucocorticoids are 
important for the structural development of organs and functional maturation of 
many key fetal tissues in preparation for birth (Speirs, Seckl and Brown 2004) and 
extrauterine life (Cheng et al. 1980, Ballard 1989).  
 
A number of studies have shown that significant maturational changes in organ 
systems, such as the lungs, heart, liver, gut and kidneys (Bian, Seidler and Slotkin 
1993, Bian, Seidler and Slotkin 1992, Celsi et al. 1997), are glucocorticoid-
dependent, and can be induced prematurely by exogenous glucocorticoid 
administration (Ballard 1979, Fowden 1995), underpinning their widespread 
therapeutic use in threatened preterm labour and in the perinatal period, particularly 
to accelerate the rate of lung maturation (Ward 1994). Furthermore, GR-null mice 
die within the first few hours after birth of respiratory failure, due to severe lung 
atelectasis, and have severely retarded maturation of the adrenergic chromaffin cells 
and hepatic gluconeogenic enzymes (Cole et al. 1995a). 
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However, there is also evidence that supraphysiological concentrations of 
glucocorticoids are harmful to the fetus. For example exogenous administration of 
glucocorticoids has been shown to retard fetal growth and produce lowered weight at 
birth in humans, non-human primates and other experimental mammals (Reinisch et 
al. 1978, Novy and Walsh 1983, Mosier et al. 1982, Berry et al. 1997, Nyirenda et al. 
1998, Seckl 1994). Furthermore, cortisol levels are increased in human fetuses with 
intrauterine growth retardation (Goland et al. 1993, Goland, Conwell and Jozak 
1995) or in pregnancies complicated by pre-eclampsia, which may indicate a role for 
endogenous cortisol in fetal growth retardation (Goland et al. 1993, Goland et al. 
1995). 
 
There may be significant differences between the effects of fetal exposure to 
endogenous glucocorticoids and those of synthetic glucocorticoids relevant to 
programming models. For example, although endogenous glucocorticoids can bind 
both GR and MR and the effects in tissues such as brain may be mediated by both of 
these receptors, synthetic glucocorticoids are more selective for MR (Drake, Tang 
and Nyirenda 2007). Similarly, there may be differences in local glucocorticoid 
concentrations in tissues, which may be governed by differences in transport (e.g. 
across the blood–brain barrier) and metabolism of endogenous and synthetic 









11β-HYDROXYSTEROID DEHYDROGENASE ENZYMES 
 
Beyond the classical modulations of circulatory glucocorticoid levels, intracellular 
glucocorticoid activity in the peripheral tissues is determined by the 11β-
hydroxysteroid dehydrogenase enzymes; type 1 (11β-HSD1) and type 2 (11β-HSD2). 
The type 1 isozyme (11β-HSD1) and type 2 isozyme (11β- HSD2) are distinct 
enzymes.  
 
11β-HSD1 is made up of a 34kDa glycoprotein consisting 187 amino acids (in rats) 
and 292 amino acids (in humans) (Lakshmi and Monder 1988). It is located 
predominantly in the liver, fat, lung, brain and testis (Stewart and Krozowski 1999, 
Monder and Lakshmi 1989). In vivo, 11β –HSD1 acts primarily as a reductase, using 
NADP(H) as a cofactor, converting cortisone to cortisol (Jamieson et al. 1995), 
thereby amplifying intracellular glucocorticoid action. 
 
Up-regulation of 11β-HSD1 may be an important key mechanism in amplifying the 
local glucocorticoid activity in key metabolic tissues such as visceral fat and/ or 
liver, which may also contribute to important pathophysiological processes (Seckl 
and Walker 2001). Indeed, in transgenic models, animals with selective over 
expression of 11β-HSD1 in visceral fat or in the liver showed features of increased 
gluconeogenesis and the metabolic syndrome, mediated by greater pro-inflammatory 
cytokines delivered to the hepatocyte in the portal circulation (Masuzaki et al. 2001). 
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Indeed, in marmosets at least, prenatal glucocorticoid treatment resulted in 
upregulation of hepatic 11β-HSD1 mRNA, possibly responsible for the later 
development of adult hyperglycemia observed in this model (Nyirenda 2009). 
 
On the other hand, 11β-HSD2 catalyses the reverse reaction: converting cortisol to 
cortisone. The human 11β-HSD2 is 41 kDa, 405 amino acids long, requires NAD
+
 as 
a cofactor and has a lower Km (2-10 nM) for steroid substrate. 11β-HSD2 is co-
localized with mineralocorticoid receptor, and is present in the kidney and placental 
microsomes in sheep and humans (Narayfejestoth, Watlington and Fejestoth 1991, 
Agarwal et al. 1994, Albiston et al. 1994) . 
 
In the kidney, 11β-HSD2 plays an important role in regulation of sodium 
reabsorption and blood pressure. By acting as a pre-receptor barrier, renal cellular 
11β-HSD2 prevents glucocorticoids from activating MR. Inactivating mutations of 
the 11β-HSD2  gene allow illicit activation of MR by glucocorticoids, resulting in 
the syndrome of apparent mineralocorticoid excess (SAME)(Stewart et al. 1988), 
characterized by increased sodium reabsorption, hypertension and hypokalemia. 11β-
HSD2 and other genes involved in renal glucocorticoid/ mineralocorticoid action are 
therefore important potential targets in programming of hypertension. 
 
11β-HSD2 also plays a critical role in the placenta where it limits glucocorticoid 
access to the fetus. Concentrations of the active glucocorticoid cortisol are high in 
maternal blood during pregnancy. Although lipophilic steroids can pass through the 
feto-placental barrier, the presence of placental 11β-HSD2 results in the rapid 
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inactivation of cortisol to inert cortisone, thus minimizing foetal exposure (Campbell 
and Murphy 1977, Seckl 1997). Indeed, reduced placental activity of 11β–HSD2 was 
associated with lower birth weight in human infants (Kajantie 2003).  Also, in 
regression analyses of AME patients with published genotypes, a lower birth weight 
was correlated with lower levels of enzyme activity (Nunez 1999), likely reflecting 
the result of increased glucocorticoid exposure to the developing infant. 
 
In support of the glucocorticoid programming hypothesis, prenatal treatment with the 
synthetic glucocorticoid dexamethasone (which bypasses the placenta barrier 
unmetabolised) or carbenoxolone (a licorice derivative with potent placental 11β-
HSD2 inhibitor activity) has been shown to increase offspring blood pressure, 
glucose and glucocorticoid levels in a number of species including non-human 
primates (Drake, Tang and Nyirenda 2007). The molecular mechanism that 
underpins glucocorticoid programming remains incompletely understood, but may 
involve coordinated alterations in glucocorticoid activity, through changes in 
receptor density and/or expression of enzymes that modulate local glucocorticoid 
























PROGRAMMING OF HYPERTENSION 
 
The programming of hypertension has been well-established by the dexamethasone 
rat model. Initial studies from our laboratory performed on rodents confirmed the 
hypothesis that excessive glucocorticoid exposure not only reduced offspring 
birthweight, but also predisposed adult offspring to higher blood pressures, glucose 
intolerance and hypercortisolism (Benediktsson et al. 1993, Lindsay et al. 1996, 
Nyirenda et al. 1998, Levitt 1996).These observations were observed in models using 
dexamethasone and carbenoxolone, a potent inhibitor of placenta 11β-HSD2, 
allowing increased endogenous maternal glucocorticoid to pass through the placental 
enzymic barrier. Dexamethasone is a poor substrate for 11β-HSD2, and in 
experimental models, prenatal administration of dexamethasone reduces birth 
weight, presumably by increasing fetal glucocorticoid load. 
 
 A similar effect is seen when the pregnant rats are treated with carbenoxolone. 
These effects of carbenoxolone are independent of changes in maternal blood 
pressure or electrolytes, but do require the presence of maternal glucocorticoids: the 
offspring of adrenalectomised pregnant rats are protected from carbenoxolone effects 
upon birth weight or adult physiology (Lindsay et al. 1996). Both male and female 
adult offspring of dexamethasone-treated pregnancies have elevated blood pressure 
(Benediktsson et al. 1993, Woods and Weeks 2005, Sugden et al. 2001, Levitt et al. 
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1996), although the mechanisms in the induction of hypertension in these models 
may be gender-specific (O’Regan 2004, McMullen 2005) 
 
These observations have now been replicated in other laboratories, using other 
mammalian species, notably sheep and monkeys. Cortisol infusion into the foetus in 
utero elevates blood pressure in sheep (Tangalakis et al. 1992, Kari et al. 1994). 
Excess cortisol also directly elevates blood pressure at birth in humans (Kari et al. 
1994) and sheep (Berry et al. 1997). However, programming to occur, such effects 
need to persist. Of note, adult hypertension is produced in sheep exposed to excess 
glucocorticoid in utero, either in the form of maternally administered dexamethasone 
or cortisol (Dodic et al. 1998, Dodic et al. 2002b, Dodic et al. 2002a, Dodic et al. 
2001b). 
 
The timing of glucocorticoid exposure appears to be important. Exposure to 
glucocorticoids during the final week of pregnancy in the rat is sufficient to produce 
permanent adult hypertension (Levitt et al. 1996). Wintour and others, however have 
found that the sensitive window for programming hypertension in dexamethasone-
treated sheep is in early gestation, in the early stages of nephrogenesis (Wintour 
2003, Dodic et al. 1998, Gatford et al. 2000, Moss et al. 2001). Such differences may 
be primarily due to the complex species-specific patterns of expression of 
glucocorticoid receptor, mineralocorticoid receptor and the isoenzymes of 11β-
HSDs, which regulate maternal glucocorticoid transfer to the foetus and modulate 




In this respect this late gestational timing is similar to human evidence on the effect 
of famine during pregnancy on later metabolic disease in the offspring, suggesting 
that glucocorticoids may be involved in human programming of chronic diseases. 
Birth weight reduction is most significant when glucocorticoids are administered in 
the latter stages of pregnancy, an acknowledged period of maximum fetal somatic 
growth (Nyirenda et al. 1998). In humans, fetal blood cortisol levels are increased in 
intrauterine growth retardation, thus implicating endogenous cortisol in retarded fetal 
growth (Goland et al. 1993, Goland et al. 1995).  
 
In our dexamethasone-programmed model, most investigators have found an 
increase of 10 mmHg of systolic blood pressure when measured using the tail-cuff 
method in adult rats (experiments were carried out on adult offspring between 4 
months to 9 months old). (Benediktsson et al. 1993, Levitt NS et al 1996, O’Regan et 
al 2004).  However, using sophisticated blood pressure measurements with 
radiotelemetry, which is unaffected by stress artefacts and therefore represents the 
gold standard in rodent blood pressure measurement, it was found that adult male 
offspring paradoxically had lower basal blood pressures in adulthood (4–8 mmHg 
lower); with the commonly expected hypertensive phenotype only being noted when 
these offspring were subjected to even mild disturbance or a more severe stressor (up 
to 30 mmHg higher than controls). They also observed that the isolated mesenteric 
vasculature dexamethasone-treated offspring had a greater sensitivity to 
noradrenaline and other vasoconstrictors and concluded that altered sympathetic 




This finding highlights the importance of the blood measurement technique in 
assessing blood pressure, as rats are usually “stressed” and restrained during tail-cuff 
measurements. Indeed, dexamethasone-programmed show a greater increase in basal 
and stress related corticosterone (Levitt NS et al 1996), a finding that has been 
replicated in human studies, as further discussed in the next section. This raises the 
interesting possibility that the raised blood pressure observed in these animals using 
the tail-cuff method could also be related to the greater corticosterone levels induced 
by stress during restraint. O’Regan also observed a longer duration of blood pressure 
increases after minor “stressors”, e.g. by an observer entering the room. This could 
mean that longer-term mechanisms, perhaps mediated by corticosterone on other 
regulatory blood pressure systems like the kidney, may be involved in this 
phenomenon, rather than the shorter term influences of the sympathetic nervous 
system. 
 
In light of this finding (of hypotension in the “non-stressed” state as measured by 
radiotelemetry), there also remains the alternative possibility that increased 
mineralocorticoid activity with increased renal sodium reabsorption may be a 
compensatory response to the lower blood pressure observed (as per Guyton’s 
observations that a decrease in blood pressure increases sodium retention). Thus, it 
would be interesting to further explore this issue and investigate if changes in 
mineralocorticoid signalling and downstream sodium retention, either as a 
compensatory mechanism in response to the hypotension observed in these adult 
animals, or as a primary change that allows corticosterone to initiate longer-term 
changes in blood pressure (or possibly both). This could be addressed experimentally 
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(e.g. by measuring if changes in mineralocorticoid signalling occur early in life 
before blood pressure changes, to determine if these changes are primary or 
secondary).   
 
Dexamethasone programming likely produces an integrated adaptive response that 
lead to hypertension. Although the mechanisms of hypertension remains 
incompletely understood, changes in basal and stress hypercortisonemia (Levitt NS 
1996), an increased sympathetic response to stress (O’Regan D, 2008) and insulin 
resistance (Nyirenda MJ 1998) have previously been observed in our model. Both 
male and female adult offspring of dexamethasone-treated pregnancies have elevated 
blood pressure (Benediktsson et al. 1993, Woods and Weeks 2005, Sugden et al. 
2001, Levitt et al. 1996), although the mechanisms in the induction of hypertension 
in these models may be gender-specific (O’Regan 2004, McMullen 2005) 
 
Michel Baum and colleagues at the University of Texas, Southwestern Medical 
Center have used a similar model of dexamethasone programming. However in their 
protocol, they used 200 mcg/kg of dexamethasone injected peritoneally daily from 
















cotransporter (NCC), but not α-, β-, and γ-epithelial Na
+
 channel (ENaC) protein 
abundance compared with controls. This was associated with increased proximal 
sodium reabsorption. Additionally, the kidneys of dexamethasone programmed 
offspring had a 20% lower number of glomeruli. In their programmed offspring, 
higher blood pressures were noticed at 8 weeks. When renal denervation was 
 
32 
performed in young offspring, no hypertension developed in adult life and the 
changes in NHE3, NKCC2, and NCC were not observed   (Baum et al 1993, Dagan 
et al, 2008). 
 
Various other fetal programming models have been used to dissect the mechanisms 
of hypertension. These models include global food restriction or protein
 
restriction 
(maternal malnutrition) during gestation (which is the best studied model), chronic 
hypoxia administered to the mother during the
 
gestational period and placental 
insufficiency.
 
 Modes of dietary manipulation include global caloric restriction, 
dietary protein reduction, iron restriction or dietary fat supplementation. These have 
been extensively studied in both rodent and ovine models. In most rodent models of 
maternal nutrient restriction, dietary manipulation is carried out until weaning when 
the offspring go onto standard laboratory chow. 
 
 Offspring of treated mothers are generally born with low birthweight. In some of the 
models, there has been observed a congenital deficit in nephron number. Reduction 
in nephron numbers would predispose the individual to reduced renal sodium 
excretion and subsequent increased susceptibility to essential hypertension, 
particularly in the setting of dietary sodium excess (Brenner, Garcia and Anderson 
1988). The exact mechanism of the reduction in nephron number has not been 





These animal models have also demonstrated that prenatal dietary manipulation 
cause reduced expression of components of the renin-angiotensin system during 
active nephrogenesis (Guron and Friberg 2000) that result in lower nephron numbers 
and hypertension in later life (Vehaskari et al. 2004, Woods et al. 2001).  
 
Furthermore, other studies suggest an interaction between low-protein programming, 
glucocorticoids and the intrarenal renin-angiotensin system, such that an excess of 
glucocorticoids seen in these models can be a negative regulator of the components 
of the renin-angiotensin system in the fetus (Celsi et al. 1998, Segar et al. 1995). 
Since it has also been shown that angiotensin II can stimulate the expression of Pax-2 
through angiotensin II type 2 receptor, negative regulation of intrarenal RAS could 
affect nephrogenesis and kidney development (Zhang, Moini and Ingelfinger 2004).   
 
Other mechanisms that have been suggested to contribute to programming of 
hypertension include permanent alterations in the activity of the renin-angiotensin 
system (Bogdarina 2006), renal 11β-HSD2 (Bertram et al 2003,, Baserga et al 2010), 
components of the cardiovascular system  altered vascular function, and  increased 
expression of the angiotensin II type 1 and 2 receptors and angiotensin-converting 
enzyme (McMillen and Robinson 2005),. There might also be altered vascular 
responsiveness to other vasoconstrictors, with enhancement of endothelin-induced 
vasoconstriction and attenuation of endothelium-dependent vasorelaxation in sheep 




Intriguingly, glucocorticoids (as stress hormones) have been suggested as a possible 
candidate mechanism that underlies these various models of programming where the 
pregnancy has been obviously subjected to stress. For instance, protein restriction in 
maternal rats was associated with higher maternal cortisol levels and increased fetal 
glucocorticoid load (Langley-Evans 1996). The programming effect (on 
hypertension) in the protein restriction model was subsequently abolished when 
maternal glucocorticoid synthesis was inhibited by metyrapone, an inhibitor of 
maternal glucocorticoid synthesis (Langley-Evans 1997), indicating that 
glucocorticoids may play a part in the programming effects at least in the protein 



















EVIDENCE FOR FETAL PROGRAMMING OF HYPERTENSION BY 
GLUCOCORTICOIDS IN HUMANS AND ITS RELEVANCE 
 
The effects of prenatal glucocorticoid exposure observed in animal models could 
have huge implications if extrapolated to the human fetus. Glucocorticoids are given 
to pregnant women for various conditions, but robust data on long term disease in 
offspring are lacking. But, as discussed below, some evidence suggests 
neurobehavioral and blood pressure changes detected as early as childhood, 
highlighting the importance to better understand the underlying mechanisms 
glucocorticoid fetal programming. 
 
The long-term effects of fetal glucocorticoid exposure in humans have been poorly 
investigated, mainly because these studies have been small and the duration of 
follow-up short. Studies aimed at establishing the long-term neurological and 
developmental effects of antenatal glucocorticoid exposure have been complicated 
by the fact that most of the children studied were born before term and were 
therefore already at risk of delayed neurological development.  
 
Glucocorticoids are used as immunosuppressants to control various maternal 
conditions, such as connective tissue disorders (Rayburn 1992), and are used 
extensively in obstetric practice, primarily to accelerate lung maturation in cases of 
threatened preterm labour (Crowley, Chalmers and Keirse 1990), which may occur in 
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up to 10% of pregnancies. There is no doubt that synthetic glucocorticoids enhance 
lung maturation and reduce mortality in preterm infants. Additionally, a single course 
of prenatal corticosteroid is associated with a significant reduction in the incidence of 
intraventricular hemorrhage and a trend toward less neurodevelopmental disability 
(Crowley 2000) . However, 98% of British obstetric departments have prescribed 
repeated courses of antenatal glucocorticoids (Brocklehurst et al. 1999), despite little 
evidence for the safety and efficacy of such a regime (Whitelaw and Thoresen 2000). 
Recent data have suggested that a short antenatal glucocorticoid exposure in preterm 
babies is associated with increased blood pressure at 14 years (Doyle et al. 2000). 
 
Yet another group of women - those at risk of bearing fetuses with congenital adrenal 
hyperplasia often receive low-dose dexamethasone from the first trimester to 
suppress fetal adrenal androgen overproduction (Carlson et al. 1999, Forest, Betuel 
and David 1989). Birth weight in such infants, however, has been reported as normal. 
Nevertheless, programming effects of antenatal glucocorticoids are seen in animal 
models in the absence of any reduction in birth weight (Forest, David and Morel 
1993, Mercado et al. 1995). Hence, careful long-term studies of this group of 
children are warranted for the presence or absence of programming effects. 
 
On the basis of findings in the prenatal dexamethasone-exposed rat model of low 
birth weight and adult hypercorticosteronemia with hypertension (Levitt NS et al 
1996), studies have examined the relationship between birth weight and 
hypothalamic-pituitary-adrenal axis function in adult humans. As in other animals, 
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the human hypothalamic-pituitary-adrenal axis appears to be programmed by the 
early life environment. 
 
Programming of the hypothalamic-pituitary-adrenal axis appears to occur in 
disparate populations (Phillips et al. 2000) and may precede overt adult disease 
(Levitt et al. 2000), at least in a socially disadvantaged South African population. 
Higher plasma and urinary  glucocorticoid levels are found in children and adults 
born with lower birth weight (Clark et al. 1996, Phillips et al. 1998). In children, low 
birth weight is associated with altered adrenocortical responses to stress in boys and 
altered basal adrenocortical activity in girls (Jones et al. 2006). In adulthood, 
hypothalamic-pituitary-adrenal axis responses to corticotrophin stimulation is 
exaggerated in offspring with low birth weight (Levitt et al. 2000, Reynolds et al. 
2001), reflecting the stress axis biology elucidated in animal models. Furthermore, 
this hypothalamic-pituitary-adrenal axis activation is associated with higher blood 














DETERMINANTS OF BLOOD PRESSURE: THE IMPORTANT ROLE OF 
THE KIDNEY 
 
Blood pressure must be tightly regulated to permit uninterrupted perfusion of all vital 
organs. For example, even transient interruption in blood flow to the brain will cause 
loss of consciousness, and longer interruptions will result in cellular hypoxia of 
unperfused tissues. Conversely, higher pressures that deliver flow exceeding 
metabolic demand provide little or no metabolic gain, but increase damage to blood 
vessels and organs. These considerations dictate the normal ranges of blood pressure 
(Lifton 2001). 
 
A wide variety of physiologic systems that have pleiotropic effects and interact in 
complex fashion have been found to influence blood pressure. Amongst these 
include baroreceptors that sense acute changes in pressure in vessels; natriuretic 
peptides produced by the brain and heart in response to increased pressure in these 
organs; the renin-angiotensin-aldosterone system, which influences vascular volume 
homeostasis and vascular tone; the kinin-kallikrein system, which affects vascular 
tone and renal salt handling; the adrenergic receptor system, which influences heart 
rate, cardiac contraction, and vascular tone; and factors produced by blood vessels 
that cause vasodilation, such as nitric oxide, or contraction, such as endothelin. These 
 
39 
systems act in an integrated fashion to ensure adequate perfusion of all tissues 
despite widely varying metabolic demand (Lifton 2001). 
 
Nevertheless, the kidney appears to be the key organ in the development of 
hypertension (Zandi-Nejad, Luyckx and Brenner 2006).  Factors intrinsic to the 
kidney itself affect blood pressure, as demonstrated in renal transplantation (both in 
humans and animals), where blood pressure in the recipient after transplantation is 
related to the hypertension risk factors of the donor; that is, hypertension “follows” 
the kidney (Rettig et al. 1990, Guidi et al. 1996). 
 
The relationship between renal sodium handling, intravascular fluid volume 
homeostasis, and hypertension, described initially by Guyton et al (Guyton et al. 
1972) using systems biology, is well accepted. Guyton thus argued that convincingly 
that for chronic high blood pressure to persist, a defect in renal sodium excretion and 
pressure-natriuresis likely is present.  
 
Genetic approaches to this disease have also begun to delineate molecular pathways 
underlying blood pressure, defining disease pathogenesis and identifying targets for 
therapeutic intervention (Lifton, Gharavi and Geller 2001). That single genes can 
impart large effects on blood pressure is demonstrated by rare Mendelian forms of 
high and low blood pressure (Lifton, 1996). Molecular genetic studies have now 
identified the exact mutations in 8 genes that cause Mendelian forms of hypertension 
and 9 genes that cause Mendelian forms of hypotension in humans. Intriguingly, all 
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of these genes are involved in renal salt and water homeostasis in the aldosterone-
sensitive distal tubules and collecting duct in the kidney. 
 
Physiologically, blood pressure determination follows Ohm's law (blood pressure 
equals to cardiac output multiplied vascular resistance). Increased salt and water 
reabsorption causes increase in cardiac output (Frank-Starling’s law) initially. 
Autoregulation occurs after the initial phase such that the cardiac output normalizes, 
whilst blood pressure is maintained by an increased vascular resistance. 
 
The kidney, via the production of erythropoietin, might also potentially affect blood 
pressure through changes in blood viscosity, in accordance with Poiseuille's law 
(below) where in a cylindrical vessel with laminar flow, blood pressure P is 
proportional its length (l), viscosity of the fluid (µ) and cardiac otput (Q), and 









It has been previously observed that prenatal dexamethasone exposure induced a 
prompt rise in foetal hepatic HNF4α mRNA. This increase occurred predominantly 
in the periportal region of the hepatic acinus and persisted into adulthood, congruent 
with the change in PCK2 mRNA (Nyirenda et al. 2006). This upregulation of PCK2, 
a rate-limiting enzyme of gluconeogenesis, probably contributed to the impaired 
glucose tolerance observed in this rodent model of dexamethasone programming. 
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The interaction between glucocorticoids and HNF4α is further supported by the 
recent identification in mouse HNF4α of an enhancer element containing a 
glucocorticoid response sequence (Bailly et al. 2001). Intriguingly,  
hypoxic regulation of EPO requires HNF4α, which is constitutively expressed in the 
major sites of EPO production: the fetal liver and the adult kidney. HNF4 binds to 
the EPO 3’ enhancer adjacent to the HIF (hypoxia-inducible factors)-binding site 
(Ebert and Bunn 1999, Mietussnyder et al. 1992), interacting with HIFs to attract 
other co-activators of EPO. We therefore speculated that HNF4α might be 





















(Please see figure) 
 
1. That the programming of hypertension following prenatal exposure to 
dexamethasone is mediated by gene expression changes in renal 
corticosteroid and/or mineralocorticoid signalling pathways, leading to 
impaired sodium excretion in the kidneys, progressing to later life 
hypertension and salt sensitivity. 
 
2. That prenatal exposure to dexamethasone increases renal production of 
erythropoietin leading to increases in plasma hematocrit and viscosity 
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Figure 1-5 Proposed hypothesis and mechanisms by which excessive 
glucocorticoid (dexamethasone) might cause hypertension,  increased salt-
sensitivity and ultimately increased cardiovascular risk through key alterations in 
the kidney- namely, renal distal tubular 11βHSD2 activity and the renal production 











All animal experiments were carried out under a UK Home Office Licence. 
Male and female Wistar rats (200-250g) were bought from Charles River 
Laboratories, Essex, UK, and maintained under conditions of controlled lighting 
(lights on from 0700hrs to 1900hrs) and temperature (22ºC) and allowed free access 
to food standard rat chow (Special Diet Services, Essex, UK) and tap water.  
 
After a week of settling in at the animal lab, rats were time-mated. Mating was 
confirmed by the identification of a vaginal plug; the day of plugging was taken as 












PRENATAL DEXAMETHASONE TREATMENT 
 





dissolved in 4% ethanol/ 0.9% saline at a final concentration of 200µg/ml) or 
vehicle (4% ethanol/ 0.9% saline) during the last week (day 15 to 21) of pregnancy. 
At least 5 pregnant rats were used per group in each experiment. At birth, the 
offspring were sexed and weighed and culled to eight pups per litter. This cohort of 
rat offspring was used for experiments done at 9 months of age.   A second distinct 
group of male offspring were bred for experiments performed at E21, 1 week old 
(real-time PCR experiments) and 2 months old (plasma electrolytes and salt-
sensitivity experiments).  This second group of male offspring was culled to 6 male 
offspring per litter.  
 
Only male offspring, selected at random from each litter, were used in all subsequent 
experiments. 
 
The number of male offspring used for tail-cuff measurements was 9 male offspring 
per group.  6 male offspring per group were used for the real-time experiments. The 
number of rats used was based on estimations for the minimal sample size as detailed 




The pups were thereafter weaned on postnatal day 21, and housed in cages 2-4 male 
offspring each cage.  
 
The offspring were killed by decapitation in either the early postnatal period (1 week 
old) or in adulthood (9 month old) to collect samples. All animals were sacrificed in 
the fed state and samples quickly frozen in liquid nitrogen and stored at -70ºC for 
subsequent analyses. 
 
In a separate cohort of animals, fetal livers from treatment and control groups were 



















BLOOD PRESSURE MEASUREMENTS 
 
In rodents blood pressure can be measured by a number of methods. The most 
accurate method is direct blood pressure measurement. This is an invasive surgical 
procedure (where blood pressure typically obtained on the rodent’s carotid artery) 
that is used as the gold standard to compare the accuracy of non-invasive 
technologies (Bunag 1973). The disadvantages of direct blood pressure methods like 
radiotelemetry include morbidity associated with the initial surgical procedure, a 
potential increase in the animal’s stress, high costs of the equipment set-up and 
maintenance, as well as the financial, equipment and human resources relating to 
surgery and anaesthesia needed for intra-arterial cannulation. 
 
The non-invasive methods of blood pressure involve utilizing a tail cuff placed on 
the rodent’s tail to occlude the blood flow. Upon deflation, one of several types of 
non-invasive blood pressure sensors, placed distal to the occlusion cuff, can be used 
to monitor the blood pressure.  
 
In our studies we employed photoplethysmography, a non-invasive blood pressure 
sensor technology which records the first appearance of the pulse while deflating the 
occlusion cuff or the disappearance of pulses upon inflation of the occlusion cuff.  
Photoplethysmography utilizes an LED light source to record the pulse signal wave. 
The choice of this method was based on the available expertise, as well as its cost 
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effectiveness. It is also technically easier to accomplish compared to direct blood 
pressure measurement. Furthermore, tail cuff plethysmography allowed 
measurements to be made in young rats, which otherwise would have been 
technically difficult with cannulation, Several previous studies have demonstrated 
that blood pressure measured by tail-cuff plethysmography shows excellent 
correlation with blood pressure simultaneously obtained by intra-arterial direct 
measurement (Ikeda, Nara and Yamori 1991, Pfeffer, Pfeffer and Frohlich 1971).  
 
The tail- cuff system used in our experiments measured blood pressure by 
determining the cuff pressure at which blood
 
flow to the tail is eliminated. Tail-cuff
 
blood pressure is defined as the cuff inflation pressure at which the waveform
 
amplitude falls below a programmable percentage of its original
 
amplitude for a 
specified number of waveform cycles. The blood pressure measurements were made 
with software purchased from the Medical Research Council (MRC) Blood Pressure 
Unit.  
 
We undertook to measure the tail-cuff blood pressure of the subjects in a blinded 
fashion.  
 
It is important to appreciate that measurement of blood pressure by 
photoplethysmography has a number of limitations. For example, it is relatively 
inaccurate because the readings are based solely on the amplitude of a single pulse 
and can only imprecisely measure the systolic blood pressure and the heart beat. 
Other limitations include over-saturation of the blood pressure signal by ambient 
 
49 
light, extreme sensitivity to the rodent’s movement (motion artifact), and difficulty in 
obtaining adequate blood pressure signals in dark skinned rodents (pigmentation 
differentiation). Tail burns can result from close contact and prolonged exposure to 
the sensors. Furthermore, diastolic blood pressure cannot be measured by 
photoplethysmography since the technology records only the first appearance of the 
pulse (the systolic pressures). Occlusion cuff length, being inversely related to the 
accuracy of the blood pressure, is also a source of variability. Longer cuffs record 
lower than the actual blood pressure measurements. Hence, standard 20-mm long 




















BLOOD PRESSURE MEASUREMENT IN ADULT OFFSPRING 
 
Blood pressure was measured in cohorts of young and old animals. In adulthood 
blood pressure was assessed in 9 month old offspring. The animals were routinely 
handled every morning (08:30-10:30 am) and accustomed to the blood pressure 
measurement routine for one week before systolic blood pressure was measured 
using tail-cuff plethysmography (equipment purchased from Harvard Apparatus, 
Kent, UK). The animals were pre-warmed to an ambient temperature of 40ºC for 
approximately 5 minutes in a warming chamber. 
 
As individual tail-cuff measurements were subject to variability
 
because of the varied 
response of individual animals to the
 
stresses (heating and restraint) involved in the 
procedure, we took a total of 4 blood pressure measurements per animal, and the 
arithmetic mean of 4 deflation cycles was used for the final computation of the 
systolic blood pressure, reducing variability.  
 
The tails of the rats were passed through a cuff (20 mm in length and 10-mm in 
diameter)
 
and immobilized by adhesive tape between
 
a light source above and a 
photoresistor below the tail. Evaluated
 
photoelectrically, blood flow in the tails 
produces oscillating
 
waveforms that are digitally sampled 200 times per second per
 
channel. The waveforms were displayed in real time on a monitor,
 
and were 
computer-analyzed before and during a programmable routine
 
of cuff inflation and 
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deflation. Programmable functions included (1) the number of waveforms analyzed
 
to identify the amplitude and heart rate before each cuff inflation,
 
(2) the number of 
preliminary unrecorded measurements, and (3)
 
the number of recorded measurements 
per session.  
 
In a further experiment, blood pressure was measured after animals had been 
pretreated with the MR antagonist spironolactone (Sigma-Aldrich, Poole, UK) 
50mg/kg per day for seven days. Spironolactone was dissolved in mineral oil, and 
administered subcutaneously. Blood pressure measurements were then measured as 



















HIGH SALT FEEDING AND BLOOD PRESSURE MEASUREMENT IN 
YOUNG OFFSPRING 
 
In a separate cohort, blood pressure was measured in animals at 2 months of age. 
Measurements were done whilst animals were on standard laboratory chow (sodium 
0.3%) and after 1 week of high salt diet (sodium 3%).  
 
It is also important to note that the potassium contents of the standard chow and high 
salt rat chow was different. The standard rat chow contained 0.69% potassium, 
whereas the high salt diet had a potassium content of 0.51%. 
 
The rationale for high salt feeding includes:  
1. To better characterize the phenotype of the affected rats 
2.  To determine any changes resulting from the effects of a high-salt diet on the 
electrolytes (serum and urine) in affected subjects 
3.  11β-HSD2 deficiency is associated with salt sensitivity 
 
High salt diet was obtained from Special Diet Services (Essex, UK). The procedure 
used to measure blood pressure in young rats was otherwise similar to that describe 
above for old animals. The animals were sacrificed to collect tissue whilst on high 






METABOLIC CAGE STUDIES 
 
Metabolic cages allow monitoring mice and rats under standardized conditions, 
enabling accurate collection of samples (such as urine and feces), as well as 
estimation of food and water intake. In our experiments, a cohort of adult rats (aged 9 
months old) was housed singly in standard metabolic cages (Harvard Apparatus, 




















EXOGENENOUS CORTISOL ADMINISTRATION 
 
To investigate the effect of glucocorticoids on urinary electrolyte concentration, 
animals from the dexamethasone and control groups were singly housed in metabolic 
cages for 3 days for acclimatization. After 3 days, a single subcutaneous injection of 
cortisol (0.5 mg/kg) at 09.00 am. Urine was then collected for a further 24 hour 
period. The concentration of electrolytes in the urine was measured by the AVL 9180 
electrolyte analyzer (Roche). Urinary aldosterone, renin and corticosterone using 


















REAL-TIME POLYMERASE CHAIN REACTION  
 
Animals were killed by decapitation in a fed state and kidneys were removed and 
immediately frozen in liquid nitrogen. All tissues were then stored in a -80ºC freezer 
for subsequent use.  Whole kidneys were homogenized in TRIZOL (guanidinium 
thiocyanate, sodium acetate, phenol and chloroform) solution (Invitrogen, Paisley, 
UK) and total RNA extracted as per manufacturer’s instruction 
(www.invitrogen.com). The basis of this method is that RNA is separated from DNA 
after extraction with an acidic solution containing guanidinium thiocyanate, sodium 
acetate, phenol and chloroform, followed by centrifugation. Under acidic conditions, 
total RNA remains in the upper aqueous phase, while most of DNA and proteins 
remain either in the interphase or in the lower organic phase. Total RNA is then 
recovered by precipitation with isopropanol and can be quantified. 
 
RNA was quantified spectrophotometrically at OD260 using the NanoDrop® ND-
1000 UV-Vis Spectrophotometer. Nucleic acids are quantified using UV absorption 
using a spectrophotometer. In its simplest form the absorbance is measured at 260 
and 280 nm. The concentration of nucleic acid can be determined using the Beer-
Lambert law, which predicts a linear change in absorbance with concentration. (An 
A260 reading of 1.0 is equivalent to about 40 µg/ml of RNA and the OD at 260 nm 
is used to determine the RNA concentration in a solution. RNA has its absorption 
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maximum at 260 nm and the ratio of the absorbance at 260 and 280 nm is used to 
assess the RNA purity of an RNA preparation. Pure RNA has an A260/A280 of 2.1.) 
Subsequently, we checked the RNA integrity by 1% agarose gel electrophoresis 
(0.5% Tris-Borate-EDTA buffer; 100 Volts/20 centimetres electrode distance; 45-60 
minute runs). The RNA was visualised in the gel by addition of ethidium bromide. 
The RNA extracted were of excellent quality: intact RNA has sharp and clear 18S 
and 28S bands, with the 28S band approximately twice as intense as the 18S band 
under UV illumination. 
To perform PCR using RNA as a starting template, the RNA must first be reverse 
transcribed into cDNA in a reverse transcription (RT) reaction. In general, reverse 
transcriptase is a multifunctional enzyme with 3 distinct enzymatic activities: an 
RNA-dependent DNA polymerase, a hybrid-dependent exoribonuclease (RNase H), 
and a DNA-dependent DNA polymerase. In vivo, the combination of these 3 
activities allows transcription of the single-stranded RNA genome into double-
stranded DNA. 
 
In our experiments, cDNA was thus synthesized from 1µg of RNA using the 
Quantitect Reverse Transcription kit (Qiagen), which incorporates a gDNA (genomic 
DNA) removal step prior to cDNA synthesis. The manufacturer’s protocol was 
followed (www.qiagen.com). Briefly, the purified RNA sample is incubated in 
gDNA Wipeout Buffer and gDNAse at 42°C for 2 minutes to effectively remove 
contaminating genomic DNA. After genomic DNA elimination, the RNA sample is 
ready for reverse transcription using a master mix prepared from Quantiscript 
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Reverse Transcriptase, Quantiscript RT Buffer, and RT Primer Mix. The entire 
reaction takes place at 42°C for 15 minutes and is then inactivated at 95°C for 3 
minutes. The resultant cDNA was then used in quantitative, real-time PCR. 
 
Real-time PCR quantification was carried out with the Lightcycler 480 real-time 
PCR system (Roche Applied Science) on 384 well plates. The Lightcycler performs 
the RT-PCR in small-volume glass capillary tubes, contained within a rotor-like 
carousel, that are heated and cooled in an airstream (Wittwer et al. 1997, Wittwer, 
Fillmore and Hillyard 1989). The carousel is rotated past a blue light-emitting diode, 
and fluorescence is read by three photodetection diodes with different wavelength 
filters that allow the use of spectrally distinct fluorescent probes (Wittwer et al. 1997, 
Wittwer et al. 1989). 
 
We used TaqMan Gene Expression Assay primers and probes purchased from 
Applied Biosystems. TaqMan probes consist of a fluorophore covalently attached to 
the 5’-end of the oligonucleotide probe and a quencher at the 3’-end. The quencher 
molecule quenches the fluorescence emitted by the fluorophore when excited by the 
cycler’s light source via FRET (Fluorescence Resonance Energy Transfer). Whilst 
the fluorophore and the quencher are in proximity, quenching inhibits any 
fluorescence signals.  
 
TaqMan probes anneal within a DNA region amplified by a specific set of primers. 
As the Taq polymerase extends the primer and synthesizes the nascent strand, the 5' 
to 3' exonuclease activity of the polymerase degrades the probe that has annealed to 
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the template. Degradation of the probe releases the fluorophore from it and breaks 
the close proximity to the quencher, thus relieving the quenching effect and allowing  
fluorescence of the fluorophore. Hence, fluorescence detected in real-time PCR is 
directly proportional to the fluorophore released and the amount of DNA template 
present in the PCR. 
 




















Table 2-1 List of primer-probes used in real-time PCR (Applied Biosystems). 
Gene  Gene symbol Assay ID 
11-beta-hydroxysteroid 
dehydrogenase type 2 
HSD11B2 Rn00492539_m1 
11-beta-hydroxysteroid 
dehydrogenase type 1 
HSD11B1 Rn00567167_m1 
Glucocorticoid receptor NR3C1 Rn00561369_m1 




Epithelial sodium channel 1-
alpha 
SCNN1A Rn00580652_m1 
Epithelial sodium channel 1-
beta 
SCNN1B Rn00561892_m1 
Epithelial sodium channel 1-
gamma 
SCNN1G Rn00566891_m1 
Hepatocyte nuclear factor 4-
alpha 
HNF4A Rn00573309_m1 
erythropoietin EPO Rn01481376_m1 
Hypoxia-inducible factor 1, 
alpha subunit 
HIF1A Rn00577560_m1 




Primers for the hnf4a-P2 Assay were custom-designed and ordered from Applied 
Biosystems:  
forward primer CTTGGTCATGGTCAGTGTGAAC;  
backward primer AGGCTGTTGGATGAATTGAGGTT;  















Hypoxia-inducible factor 1, 
beta subunit 
HIF1B Rn00562847_m1 







Tata binding protein, tbp (Assay ID Rn01455648_m1) was used to normalize the 
mRNA levels of the genes of interest. (Preliminary experiments established that tbp 
mRNA expression did not alter with prenatal dexamethasone treatment when 
normalized to the control genes 18SrRNA and β-actin.) Serial 1:2 dilutions (with 
RNase-free water) of stock cDNA (pooled from all samples) were used to create a 
standard curve. No-template negative controls (nuclease-free water) and negative RT 
controls were added to the real-time plate. Each sample was run in duplicate and the 
mean value of the duplicates was used to calculate the transcript level. 
 
The error for the standard curve thus obtained using the Lightcycler480 system was 
generally <0.01, and the standard crossing point cycle threshold (Cp) for the 
duplicate samples was 0.3 or less, which are well within the accepted ranges for 
















11β-HSD2 ENZYME ASSAY 
 
11β-HSD2 is an exclusive 11β-dehydrogenase, and uses NAD as a cofactor to 
convert corticosterone (B) to 11-dehydrocoticosterone (A). Fresh kidneys were 
homogenized in a medium containing 20% glycerol, 4 mM tris (hydroxy- methy1) 
methylamine (Tris) and 1mM EDTA (pH 7.5). Protein content was then quantified 
using the Bradford protein assay, which is based on the observation that the 
absorbance maximum for an acidic solution of Coomassie Brilliant Blue G-250 shifts 
from 465 nm to 595 nm when binding to protein occurs.  
 
To initiate the reaction, tissue homogenate (final reaction concentration of 0.2mg 
protein/ml) was incubated at 37
o
C with 400µm NAD and 10 nM [
3
H]-B in an assay 
buffer (10% glycerol, 300mM sodium chloride, 1mM EDTA and 50 mM Tris; pH 
7.7). The reaction was terminated by placement on ice after 10 minutes. Steroids 
were extracted by ethyl acetate and quantified by high-performance liquid 
chromatography (HPLC) in mobile phase (65% water, 15% acetonitrile, 25% 
methanol). The ratio of A/ (A+B) steroids was used to calculate the enzyme activity 
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of renal 11β-HSD2, expressed as pmol product/mg protein/minute. All reagents used 






ENZYME LINKED IMMUNOASSAYS AND ELECTROLYES 
 
PLASMA ERYTHROPOIETIN CONCENTRATION 
 
Samples were obtained between 8:30 and 10:00am from 9 month old animals in a fed 
state. Blood was collected by tail-tipping into heparinized tubes and spun at 5000 g 
for 5 minutes to obtain plasma. The samples were stored at -20ºC for subsequent 
analysis using a validated Rat Erythropoietin ELISA kit (USCN Life Science, 
Wuhan, China). The interassay and intraassay coefficients of variation were 7.3% 
and 6.6%, respectively. The sensitivity of the assay was less than 0.7 ng/ml. 
 
Blood to determine plasma concentrations of renin, aldosterone, corticosterone and 
electrolyte concentrations was collected in the morning between 9:00 and 10:00 am. 
After tail tipping, free-flowing drops of blood were collected into heparinized 
Eppendorf tubes and spun immediately (2000g x 10 min). Electrolytes were 
measured using an AVL 9180 electrolyte analyzer (Roche, Switzerland) within 1 
hour. Plasma samples to measure aldosterone and renin concentrations were stored at 
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-20ºC for subsequent analyses. Plasma renin was measured by enzyme linked 
immunoassay (ELISA) using a validated kit supplied by USCNLIFE (Wuhan, 
China), intraassay and interassay coefficients of variation <8%. Aldosterone was 
measured by a validated ELISA kit (Alpha Diagnostics International, Texas, USA). 
Intraassay and interassay coefficients of variation were <6% and <10%, respectively. 
Corticosterone levels were measured by a validated ELISA kit (AssayPro, St. 





























Whole fresh kidneys were fixed in formalin for 24 hours and embedded in paraffin 
using standard procedures. Multiple adjacent 4 mm sections of the mid-transverse 
kidney were cut and mounted on glass slides. The sections were stained with 
hematoxylin and eosin. Glomeruli and tubule segments were identified based on 
positional and morphological criteria by a blinded observer. Morphometric 
measurements were taken using MCID image analysis using the Zeiss Axiovert 25 
Phase Light Microscope. The range of magnification includes 5x, 10x, and 40x. The 
glomeruli number was counted under the 40x magnification field. The camera model 
employed was CoolSnap Photometrics with the software used being MCID Basic 
7.0. 
 
A total of 9 rats per group were sacrificed at 9 months of age. Transverse cuts 
through the mid kidneys, for consistency, were obtained for each rat and put on 
slides (3 slides per animal). The average number of glomeruli per 40x magnification 
field was counted in 5 random subcortical fields per slide in a blinded fashion. 
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(Zeiss). The average number of glomeruli per 40x magnification field per rat was 
then computed as the average of the 3 slides, and was used for comparison between 
the 2 groups.   
 
In a similar fashion, the average diameter of all glomeruli under 40x magnification 
was measured in 5 random subcortical fields per slide. The average of 3 slides per 
animal was used for the subsequent comparison of the glomerular diameters between 



























Immunostaining was performed on 4mm mid-transverse sections of paraffin-
embedded whole kidney. Sections were dewaxed in xylene and rehydrated through 
graded alcohols and subjected to pressure cooking in 0.01 M citrate (pH 6.0) buffer 
for antigen retrieval. Endogeneous peroxidase activity was inactivated in 3% 
(vol/vol) hydrogen peroxide in methanol for 30 minutes, followed by blocking of 
endogenous avidin-binding sites using an avidin/biotin kit (Vector Laboratories, 
Peterborough, UK), according to the manufacturer's protocol. Nonspecific staining 
was blocked by incubation with appropriate normal serum (Autogen Bioclear UK 
Ltd.) diluted 1:5 in TBS containing 5% BSA (Sigma-Aldrich Co. Ltd., Dorset, UK) 
for 30 min. Sections were incubated with polyclonal sheep anti-  11bHSD-2 antibody 
(dilution 1: 1000) overnight in a humidified chamber at 4°C. After two 5 min washes 
in TBS, the sections were incubated for 30 min with biotinylated anti-sheep 
antibody, diluted in normal serum. This was followed by two further 5 min washes in 
TBS, and incubation for 30 min with Streptavidin-horse-radish peroxidase at 1:1000 
(Dako, Ely, UK) diluted in TBS. Staining was visualized using 3,3-diaminobenzidine 
tetrahydrochloride chromagen (DAB Substrate kit, Vector Laboratories, 
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Peterborough, UK). Sections were counterstained with haematoxylin, dehydrated in 
graded alcohols and immersed in xylene before mounting in Pertex mounting 
medium (CellPath plc, Hemel Hempstead, UK). To ensure reproducibility of results 
and allow accurate comparison of immunostaining between groups, sections of 
kidney from control and dexamethasone-treated animals were processed in parallel. 
Appropriate negative controls were included, by replacing them with polyclonal 
sheep anti- 11βHSD-2 antibody with appropriate normal serum, to ensure that any 



























All data are expressed as means ± SEM. Data were compared using unpaired 
student’s t tests or one-way ANOVA followed by Newman-Keuls post-hoc multiple 
comparisons test, where appropriate. Values were considered significant at p<0.05. 
GraphPad software version 4.0 was used. 
 
 Determination of the smallest sample size was calculated using an online statistical 
resource (http://www.stat.ubc.ca). This calculation is based on the standard sample 
size calculation for unpaired sample means. (Fundamentals of Biostatistics, 6th 
edition, by Bernard Rosner), where n, the minimal sample size required is calculated 
as follows The letter "z" represents a standard normal distribution. Alpha represents 
the probability of a Type I error (taken to be 0.05). Beta represents the probability of 
a Type II error (taken to be 0.20). Sigma represents the standard deviation and, D is 
the clinically relevant difference (taken as 5 mmHg). The values of sigma (the 
standard deviation) and mean blood pressure were based on previous estimations in 
studies of blood pressures of dexamethasone-treated offspring by measured by the 








This calculation yielded a minimum sample size of 6 rats per group to satisfy the 
above statistical requirements for blood pressure measurements. 
 
Similarly, the minimum sample size needed to detect a clinically relevant difference 
of 25% in gene expression was 6 rats per group based on the standard deviations 
derived from pilot real-time PCR studies (sigma less than 0.16 when means were 

























The association between low birth weight and later life hypertension is strongly 
documented in the literature (Barker et al. 1993, Benediktsson et al. 1993, Seckl 
1993, Seckl and Brown 1994, Seckl et al. 1995, Seckl 1997, Seckl et al. 1999, Seckl, 
Cleasby and Nyirenda 2000, Seckl 2001, Seckl and Meaney 2004, Seckl 2004, Seckl 
and Holmes 2007). Various animal models, using a variety of prenatal insults such as 
glucocorticoids (stress hormones), maternal hypoxia, maternal malnutrition and 
uterine artery ligation, all identify the prenatal period as a critical window for 
programming of offspring hypertension (Speirs, Seckl and Brown 2004). 
 
Work previously done in our laboratory had used the daily injection of subcutaneous 
dexamethasone to pregnant Wistar rats as a model of fetal programming. The 
offspring were shown to have lower birthweight and developed later life 
hypertension and diabetes, two salient features of the metabolic syndrome which 
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contribute to increased atherosclerosis, risk of stroke and coronary artery disease 
(Bertram and Hanson 2001, Seckl and Holmes 2007, Bertram and Hanson 2002). 
 
Using this model, key features of glucocorticoid fetal programming were defined. 
The last trimester of gestation (embryonic days 15 to 21 in the 3 week pregnancy of 
rodents) was identified as the critical period of programming hypertension and 
hyperglycemia (Seckl et al. 2000, Drake, Walker and Seckl 2005, O'Regan et al. 
2004, Seckl 2004).  
 
 Glucocorticoid exposure in this period is sufficient and necessary for programming 
effects on offspring phenotype. Secondly, gender-specific programming effects on 
offspring have been documented. For instance, only prenatal dexamethasone-
programmed female offspring had elevated hepatic angiotensin mRNA expression, 
plasma angiotensinogen and renin activity that developed with the hypertension 
(O'Regan et al. 2004). Thirdly, previous studies have provided insight into the 
pathophysiological mechanisms of hypertension in these offspring. Some important 
pathophysiological mechanisms implicated include reactive hypercortisolemia to 
stress (in part due to decreased feedback sensitivity in the HPA axis), greater 
sympathetic nervous response to stress, and greater increases in plasma renin and 
angiotensinogen (in female offspring) (O'Regan et al. 2004).  
 
Other investigating groups, using different paradigms, have found decreased nephron 
numbers (Brenner, Garcia and Anderson 1988, Gilbert et al. 2005, Langley-Evans, 
Welham and Jackson 1999, Ortiz et al. 2003, Vehaskari, Aviles and Manning 2001, 
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Wintour et al. 2003, Woodall et al. 1996, Woods et al. 2001, Woods, Weeks and 
Rasch 2004) and mass, hyperaldosteronemia, impaired endothelium- dependent 
vasorelaxation (Schulz, Anter and Keaney 2004, Goodfellow et al. 1998, Leeson et 
al. 2001, Cripps, Martin-Gronert and Ozanne 2005, Panza et al. 1990) and decreased 
expression of renal 11β-HSD2 enzyme to be important in programming.  
 
What is emerging from these studies, however, is that excessive exposure to 
glucocorticoids prenatally appears to effect coordinated changes in glucocorticoid 
action in the tissues. For instance, tissue-specific GR expression is affected; 
decreased GR expression in the hippocampus and the amygdala decreases the 
negative feedback of plasma hypercortisolism and leads to a higher basal rise in 
cortisol (Welberg et al. 2001). In the liver, GR expression was increased. This, 
coupled with the increased 11β-HSD1 enzyme in livers observed in marmoset 
primates, may contribute to increased liver gluconeogenesis, in part mediated by 
upregulation of Pck2 (Nyirenda et al. 1998), a rate-limiting enzyme in 
gluconeogenesis (Pilkis and Granner 1992) and an important glucocorticoid target.  
 
The aims of the studies in this chapter were to confirm the effects of prenatal 
overexposure to glucocorticoids on offspring blood pressure and to examine the 
















THE EFFECT OF PRENATAL DEXAMETHASONE ON BIRTH WEIGHT, 
MATERNAL WEIGHT GAIN AND LITTER CHARACTERISTICS 
 
In accord with previous studies, offspring of dams that were treated with 
dexamethasone in the last trimester (days 15 to 21 gestation) had a modest but 




Figure 3-1 Effect of prenatal dexamethasone on 9 month old offspring body weight. 
***=p<0.001 compared to controls. n=83 and n=97 for control and dexamethasone-
treated group respectively.  
Dams that received dexamethasone during pregnancy had significantly reduced 
weight gain once dexamethasone injections were started, compared to those that 
received vehicle (Table 3-1). This effect has been observed previously, and may be 
reflect a direct effect of dexamethasone on fetal growth, resulting in smaller fetuses 
with intrauterine growth retardation (Reinisch et al. 1978). Alternatively, the 
decrease in gestational weight gain may result from the effects on the mother, as 
dexamethasone has been shown to reduce maternal food intake (Jahng et al. 2008). 
Interestingly, although the maternal weight gained was 46% lower in the 
dexamethasone-treated dams (p=0.0006) 4 days after injections were begun, the 
maternal weight gained at 7 days (after injections were begun) was only 37% 
(p=0.0004) lower in the dexamethasone-treated group, suggesting some degree of 
‘catch-up’ in maternal weight gain, possibly due to placental hypertrophy, fetal 













Group Maternal weight gained after 4 
days of injections, grams 
Maternal weight gained after 7 











Control (vehicle injections) 
DEX (dexamethasone) 
 
Table 3-1 Effect of prenatal dexamethasone on the maternal weight gained after 
injections were started on Day 15 of gestation. The weight gain of the pregnant dams 
was followed up after 4 days (Day 19 of gestation) and 7 days (Day 21 of gestation) 








Litter characteristics such as gestation length, litter size or male: female ratio in 
offspring were not affected by maternal treatment with dexamethasone at the dosage 















22±0.11 13.57±0.92 1.66±0.73 
 
Table 3-2 Effect of prenatal dexamethasone on gestational length, litter size and male 









THE EFFECT OF PRENATAL DEXAMETHASONE ON POSTNATAL 
OFFSPRING WEIGHT AND KIDNEY WEIGHT 
  
At birth, the offspring were culled to 8 males per litter. No further manipulations 
were made to the mothers and animals were kept under similar conditions. The 
offspring were weaned at the age of 21 days. By age 1 month, the dexamethasone -
programmed offspring had caught up in weight with their control litter-mates 
(p=0.70). Henceforth, when examined at 5 months and 9 months old, the body 
weight in dexamethasone-programmed offspring was not significantly different from 














Group Body Weight at 1 
week, grams 
Body weight at 1 
mth, grams 
Body weight at 
5 mths, grams 




26.80±0.65 47.60±0.75 584.6±15.45 669.0±29.3 
DEX 
(n=9) 
22.80±0.93** 46.90±1.07 576.6±17.98 642.6±13.3 
 
Table 3-3 Effect of prenatal dexamethasone on body weight at 1 week, 1 month, 5 
months and 9 months respectively. **= p<0.01 compared to the control group. 
 
 
Prenatal treatment with dexamethasone was associated with a subtle (10%) but 
significant decrease in kidney weight at 1 week (p=0.0005). However, when 
normalized to body weight, there were no differences in kidney weights between 
dexamethasone-programmed offspring and controls, either at 1 week of age or in 









Group 1 week body wt 
 
grams 
1 week kidney weight, 
grams 
1 week normalized 
 
 kidney weight g/kg 
Control 
(n=9) 
26.80±0.65 0.335±0.009 12.52±0.32 
DEX 
(n=9) 




Group 9 mth body wt 
 
grams 
9 mth kidney weight, 
grams 
9 mth normalized 
 
 kidney weight g/kg 
Control 
(n=9) 
669.4±29.3 4.19±0.17 6.30±0.18 
DEX 
(n=9) 
642.6±13.3 4.00±0.09 6.24±0.14 
 
 
Table 3-4 Dexamethasone-treated offspring vs. control litter-mate kidney and body 
weights at 1 week (A) and 9 months (B) of age **=p<0.001; ***=p<0.0001 






THE EFFECT OF PRENATAL DEXAMETHASONE ON OFFSPRING 
BLOOD PRESSURE, URINARY SODIUM EXCRETION AND PLASMA 
ELECTROLYTES 
 
Offspring systolic blood pressure was determined by tail-cuff plethysmography. In 9 
month old adult offspring, there was a significant increase in the systolic blood 
pressure (12 mmHg) in the dexamethasone -programmed animals when compared to 
controls (p=0.008).  
























Fig 3-2 There was a significant increase in the systolic blood pressure in the 
dexamethasone -programmed animals when compared to controls (p<0.05). n=9 per 
group. 
control 
  dexamethasone 
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We examined urinary sodium excretion in 9 month old offspring using metabolic 
cages. Despite having higher blood pressures, the dexamethasone-programmed 
animals had a similar rate of urinary sodium excretion (dexamethasone-treated 
group, 1.22±0.09 mmol/24 hours; controls, 1.21±0.15 mmol/24 hours; p=0.93. This 
is consistent with either a shift of the pressure-natriuresis curve to the right or a 
gentler slope in the pressure-natriuresis curve, implying a lesser degree of renal 
sodium excretion (since the dexamethasone-programmed offspring have a higher 
blood pressure and would hence be expected to have a higher, not similar rate of 
urinary sodium excretion). Urine output (dexamethasone-treated group, 16.67±1.52 
mls; controls, 16.67±1.52; p=1.00) and drinking rates (dexamethasone-treated group, 
36.7±4.2 mls; controls, 30.0±3.6 mls; p=0.76) were not significantly different 














Plasma electrolytes were examined as an index of mineralocorticoid activity. 
Although there was no difference in plasma sodium (p=0.76), plasma potassium was 




Table 3-5 Effect of prenatal dexamethasone on plasma concentrations of electrolytes 





















Animals were placed on spironolactone at the age of 12 months. At this age, baseline blood 
pressure measurements were higher than those obtained at 9 months of age, but animals that 
were born to mothers that received dexamethasone during pregnancy continued to have 
higher blood systolic blood pressure compared control rats (DEX, 152.2±4.0; Control, 
141.8±3.1 mmHg; p=0.06). However the difference in blood pressure between the groups 
was completely abolished after a week’s treatment with spironolactone (DEX, 143.1±2.9; 
Control, 143.3±2.1 mmHg; p=0.89). 
 
To examine whether these changes tracked from early life, we next examined a 
separate cohort of younger animals at age 2 months. In these younger animals, 
systolic blood pressure, plasma sodium and plasma potassium were not different 
between the dexamethasone -programmed offspring and the controls. (p=0.98, 

















THE EFFECT OF PRENATAL DEXAMETHASONE ON SALT SENSITIVITY 
 
In order to further characterize the effect of prenatal dexamethasone treatment on 
renal sodium handling and blood pressure control, we compared the effect of high-
salt feeding on blood pressure in the 2 month old offspring that had been prenatally 
exposed to dexamethasone or vehicle.  
 
Group Blood pressure mmHg 
Standard Diet 
Blood pressure mmHg 






118.6±1.8 129.0±2.7 * 
 
Table 3-6 Effect of prenatal dexamethasone on salt-sensitivity in 2 month old 
offspring on standard 0.3% sodium diet and after 1 week of 3% sodium (high-salt) 
diet. Means were compared using 1-way ANOVA and Newman-Keuls post-hoc 






After one week of high salt diet (3% Na content vs. 0.3% Na in standard rat chow), 
the dexamethasone-programmed offspring developed higher systolic blood pressures 
(dexamethasone-treated group, 129.0±2.7 mmHg; controls, 120.8±2.5 mmHg; 
p<0.05) compared to controls. As observed in the older (9 month old) offspring, this 
salt-sensitive increase in blood pressure was accompanied by significant lower 
plasma potassium in the dexamethasone-treated group when compared to controls 
(decrease of 0.7mmol/L). There were no differences in plasma sodium between the 2 
groups after high salt feeding, although the sodium levels in both groups were higher 
after 1 week of high salt feeding when compared to baseline. 
 
Group plasma sodium, mmol/L 
Standard Diet 
Plasma sodium, mmol/L 
High Salt Diet 
Control 
(n=8) 
140.4±0.3 143.4±0.60*  
DEX 
(n=8) 
139.7±0.6 143.0±0.84 ** 
 
 
Table 3-7 Effect of prenatal dexamethasone on 2 month old offspring plasma sodium 
on standard 0.3% sodium diet and after 1 week of 3% sodium (high-salt) diet. Means 
were compared using 1-way ANOVA and Newman-Keuls post-hoc testing. * = 
p<0.05 when Control on high salt group is compared to both Control and DEX 
groups on standard diet. **= p<0.05 when DEX on high salt group is compared to 





Group Plasma potassium, mmol/L 
Standard Diet 
plasma potassium, mmol/L 






4.22±0.07 3.28±0.20 *, ** 
 
Table 3-8 Effect of prenatal dexamethasone on 2 month old offspring plasma 
potassium on standard 0.3% sodium diet and after 1 week of 3% sodium (high-salt) 
diet. Means were compared using 1-way ANOVA and Newman-Keuls post-hoc 
testing. *= p<0.001 when DEX on high salt group is compared to both Control and 
DEX groups on standard diet. ** = p<0.01 when DEX on high salt group is 















THE EFFECT OF PRENATAL DEXAMETHASONE ON OFFSPRING 
RENIN, ALDOSTERONE AND CORTICOSTERONE 
 
The hypertension and hypokalemia seen in the dexamethasone-programmed 
offspring was indicative of increased mineralocorticoid activity in the kidney. This 
was supported by reduced plasma renin concentrations (decrease of 45%, p=0.01) 
and volume expansion, features of increased mineralocorticoid activity. Intriguingly, 
offspring of dexamethasone -treated dams had significantly lower 24-hour urine 
aldosterone concentration that controls (decrease of 55%, p=0.006); there was also a 





































Table 3-9. Effect of prenatal dexamethasone on plasma renin, plasma aldosterone 
and 24 hour urine aldosterone in 9 months old offspring. *=p<0.05 and **=p<0.01 
vs. control respectively.  
 
9 am plasma corticosterone (DEX, 39.23±4.41; control, 39.00±4.19 ng/ml; p=0.97) 
and 24-hour urinary corticosterone (DEX, 65.39±5.79; control, 41.08±10.62 
ng/ml/24 hr/kg body weight; p=0.06) were not significantly different between 
















In this chapter, our experiments were aimed at further characterization of the 
phenotype of the dexamethasone -programmed offspring. Only male offspring were 
used in these experiments. This is because dexamethasone -programming has been 
shown to result in gender-specific changes adult physiology, and, secondly, blood 
pressure in female rats varies with the oestrous cycle, and coordinating blood 
pressure measurements during the oestrous cycle would have been technically 
demanding. 
 
In accord with previous studies using tail-cuff measurements, blood pressure in adult 
offspring was elevated in animals born to dams that were treated with 
dexamethasone, both at 9 months and 12 months. The degree of systolic blood 
pressure elevation (12mmHg), if extrapolatable to humans and viewed from a whole 
population rather than an individual basis, would contribute significantly to mortality 
and morbidity. 
 
In our experiments, we did not detect a higher blood pressure at 2 months of age. 
Others in our laboratory have examined blood pressure from 4 months of age, 
whereby blood pressure changes are already observed. Baum and colleagues, using a 
very similar model of programming, but using dexamethasone administered 
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intraperitoneally at 200mcg/kg/day (twice the dosage used in our studies), have 
found that the programmed offspring developed higher blood pressures at 2 months.  
 
We offer 2 reasons: firstly, the dexamethasone programmed offspring might indeed 
have higher blood pressures, but the difference in blood pressures in this younger 
cohort was numerically small and the study was insufficiently powered to measure 
any difference. Secondly, the programming model used in our experiments may 
differ fundamentally. For instance the degree of changes in parameters such as 
normalized renal weights, glomerular diameters and glomerular numbers were not 
observed when compared to some of the other programming models (results 
presented in Chapter 4). Without these additional renal perturbations, the degree of 
blood pressure difference may not have been detected in the younger cohort.  
 
Nonetheless, our data support the idea that blood pressure changes amplify with age; 
although we did not detect blood pressure changes in the younger (2 month old) rats, 
the dexamethasone -programmed offspring had significantly higher systolic blood 
pressures at 9 months of age.  
 
Although the baseline urinary sodium excretion over 24 hours was not different in 
adult control and the dexamethasone programmed offspring at 9 months, this is 
consistent with either a shift of the pressure-natriuresis curve to the right or a gentler 
slope in the pressure-natriuresis curve, implying a deficit in renal sodium excretion 
(since the dexamethasone-programmed offspring have a higher blood pressure and 
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would hence be expected to have a higher, not similar rate of urinary sodium 
excretion).  
 
We thus examined salt-sensitivity in the younger 2 month rats which did not display 
blood pressure differences. Salt-sensitivity is widely held to be an important 
independent factor of cardiovascular morbidity and mortality, independent of blood 
pressure (Morimoto et al 2007, Weinberger et al 2001). Moreover, some 
investigators have noted the increased risk of developing high blood pressure in salt-
sensitive individuals. In low birth weight individuals, an increased salt-sensitivity has 
been observed. It was thus relevant to investigate salt-sensitivity in our younger 
cohort of programmed offspring, before the development of higher systolic blood 
pressures.  
 
Intriguingly, despite the lack of differences in blood pressure in the younger animals, 
“stressing” this cohort with high-salt feeding brought out the hypertensive 
phenotype, which suggested the presence of an underlying abnormality in salt-
handling. Unfortunately, the cohort of younger rats was not followed up 
subsequently to see if the effect of short-term high salt feeding on blood pressure was 
transient or persistent.  
 
Many mechanisms of salt-sensitivity have been proposed and study. Here we discuss 
2 potential mechanisms relevant to our programming model, namely a higher level of 
sympathetic nervous activity with greater pressor activity (Campese et al 1993) and 
decreased renal 11β-HSD2 activity (Bailey et al. 2011). O’Regan has previously 
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demonstrated that in this model of programming, the vasculature (mesenteric 
arteries) displayed greater vasoconstrictive response to noradrenaline and other 
vasoconstrictors (O’Regan et al 2008). These programmed offspring also showed a 
greater response in blood pressure to catecholamines. This is in accord with the 
observations of Campese and colleagues. In their study of 11 salt-sensitive patients 
and 14 salt-resistant patients, they found increased vasopressor reactivity to 
noradrenaline, and suggested that this may be an important mechanism for salt-
sensitivity. 
 
Interestingly, Bailey and colleagues have used the 11β-HSD2  haploinsufficiency 
mice and found that these animals develop salt-sensitive hypertension, This  
recapitulates the salt-sensitivity observed when licorice, an inhibitor of 11β-HSD2  is 
administered  in human subjects (Ferrari P et al 2001) and serves as a very useful 
model for dissecting the mechanisms of salt-sensitivity in 11β-HSD2 insufficiency.  
 
Working on this model, Bailey et al have noted that a high salt diet causes a 
progressive rise in plasma corticosterone, which likely is involved in salt-sensitivity, 
given that GR antagonism, but not MR antagonism, prevented the rise in salt-
sensitive blood pressure. Corticosterone levels were not measured during high salt 
diet in our animals, but we noted a rise in the plasma urinary corticosterone levels in 
the adult offspring, in accord with previous observations of hypercorticosteronemia 





Another interesting observation was that dexamethasone-programming was 
associated with significant hypokalemia, either spontaneously in adulthood or 
provoked by high-salt feeding in the younger offspring. Hypokalemia, in the context 
of hypertension, is typically seen with increased renal mineralocorticoid activity, 
where sodium is retained by the distal renal tubules in exchange for potassium 
excretion.  
 
In our rat model, the dexamethasone-programmed group did not display 
hypernatremia when compared to controls (when fed on standard diet). This 
phenomena (known as mineralocorticoid escape) is also a common feature of 
mineralocorticoid excess in humans; primary hyperaldosteronism and excess 
exogenous mineralocorticoid result in transient renal sodium retention which then 
returns to neutral sodium balance within a few days. This “escape” from 
mineralocorticoid-induced renal sodium retention appears to be mediated largely by 
extracellular fluid volume expansion (Knox et al. 1980, Hall et al. 1984), but the 
exact mechanisms are poorly understood.  
 
In accord with this apparent increased renal mineralocorticoid activity (and thereby 
expansion of the intravascular volume), plasma renin concentration was lower in the 
dexamethasone -programmed animals. Paradoxically, the animals had significantly 
lower 24-hour urine aldosterone concentration. The constellation of low-renin 
hypertension, hypokalemia and lowered aldosterone levels is reminiscent of the 
syndrome of apparent mineralocorticoid excess (Mune et al. 1995, Kotelevtsev et al. 
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1999), either due existence of an atypical hormone or a result of intrinsic overactivity 
of the mineralocorticoid system within the kidney. 
 
Patients with the syndrome of apparent mineralocorticoid excess  have impaired 
conversion of cortisol to cortisone due to absence of the enzyme 11β-hydroxysteroid 
dehydrogenase (Ulick et al. 1979, Campino et al. 2010). In vivo, cortisol circulates at 
concentrations up to 1000-fold higher than aldosterone. However almost all MR 
activation in vivo is mediated by aldosterone. Surprisingly, in vitro, cortisol activated 
MR with a potency similar to that of aldosterone. This observation, together with the 
biochemical findings in syndrome of apparent mineralocorticoid excess , suggested 
that the specificity of MR for aldosterone in vivo is mediated indirectly, with 11β-
HSD “protecting” MR from cortisol by metabolizing it to cortisone, which does not 
activate MR (Funder et al. 1988, Stewart et al. 1988).  
 
In the syndrome of apparent mineralocorticoid excess, the absence of 11-βHSD 
allows cortisol to activate MR, resulting in hypertension mediated by increased 
ENaC activity. The 11β-HSD2 gene, which is expressed in the same cells of the 
nephron that express ENaC, shows homozygous loss-of-function mutations in 
syndrome of apparent mineralocorticoid excess patients (Mune et al. 1995).  
 
Chronic ingestion of large quantities of natural licorice can inhibit 11β-HSD2 and 
also results in hypertension with suppressed renin and aldosterone.  This is due to the 
action of a licorice metabolite, glycerrhetinic acid (Stewart et al. 1988), which is a 
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potent inhibitor of 11βHSD, producing a phenocopy of syndrome of apparent 
mineralocorticoid excess.  
 
The clinical features of syndrome of apparent mineralocorticoid excess 
(hypertension, hypokalemia, low renin, and low aldosterone) are also similar to those 
of Liddle Syndrome, an autosomal dominant disorder with early onset hypertension 
associated with hypokalemic alkalosis, decreased plasma renin activity, and low 
plasma aldosterone levels. Liddle syndrome is caused by mutations in either the β or 
the γ subunit of ENaC that delete their cytoplasmic C termini (Shimkets et al. 1994, 
Hansson et al. 1995).  
 
Other groups have used dexamethasone-programming models and found increased 
sodium reabsorption upstream to the aldosterone-sensitive distal nephron (Baum M, 
2008). Indeed, the aldosterone-sensitive distal nephron is involved in just the 
excretion of 2-3% of the filtered sodium load in the kidney, whilst the more proximal 
tubules are responsible for the excretion of 97% of the filtered load. Nonetheless, 
monogenic mutations in humans, which involve sodium and virtually all secondary 
causes of hypertension including primary hyperaldosteronism, renal artery stenosis, 
phaeochromocytoma, involve net increase of sodium reabsorption at the level of the 
aldosterone-sensitive distal nephron.  
 
Importantly, the phenotype observed  (low renin, low aldosterone, hypokalemic 
hypertension and salt-sensitivity) in our dexamethasone-programmed rat, is 
compatible with a decrease in distal nephron 11β-HSD2 .  We also note that MR 
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antagonism by spironolactone abolished the rise in blood pressure in the 12 month 
old programmed offspring.  Considered together, the aldosterone-sensitive distal 
nephron, in particular 11β-HSD2 and/or MR, are plausibly altered by 
dexamethasone-programming.  
 
Indeed, other groups using uterine artery ligation or the maternal protein restriction 
model have found changes in the aldosterone-sensitive distal nephron, including 
decreased 11β-HSD2 (Bertram CE et al 2003, Baserga et al 2010). Hence, we 
postulate that changes in the aldosterone-sensitive distal nephron may be operative in 
mediating the blood pressure changes observed in our model. These potential 




















Previous studies have shown glucocorticoids program hypertension. The mechanisms 
are unclear. A number of studies (and normal physiology) suggest that the kidney is 
important in pathogenesis of hypertension. Our data in this chapter is also supportive 
of this observation. In particular, we have demonstrated that dexamethasone 
programming is associated with reduced plasma potassium concentration and 
increased salt-sensitivity. The unique phenotype of low renin, low aldosterone 
hypokalemic hypertension suggests increased intrinsic (intrarenal) mineralocorticoid 
activity, typical of syndrome of apparent mineralocorticoid excess. This concept, 
particularly the effect of dexamethasone on renal 11β-HSD2 expression, is the 
















EFFECTS OF PRENATAL DEXAMETHASONE TREATMENT ON RENAL 






In the previous chapter, we established that prenatal dexamethasone treatment in the 
last trimester predisposed male offspring to hypertension, and that this is 
characterized by hypokalemia, low renin and low aldosterone concentrations. This is 
indicative of either existence of an atypical hormone with mineralocorticoid-receptor 
activity or intrinsic overactivity of the mineralocorticoid system within the kidney, 
resembling SAME (Mune et al. 1995, Kotelevtsev et al. 1999). Patients with this 
disorder (SAME) have impaired conversion of cortisol to cortisone due to absence of 
the enzyme 11β-hydroxysteroid dehydrogenase (Ulick et al. 1979). SAME can also 
be induced by chronic ingestion of large quantities of natural licorice due to the 
action of a licorice metabolite, glycerrhetinic acid (Stewart et al. 1988), which is a 
potent inhibitor of 11β-HSD2. 
 
The clinical features of SAME (hypertension, hypokalemia, low renin, and low 
aldosterone) are also similar to those of Liddle Syndrome, an autosomal dominant 
 
100 
disorder with early onset hypertension associated with hypokalemic alkalosis, 
decreased plasma renin activity, and low plasma aldosterone levels. Liddle syndrome 
is caused by mutations in either the β or the γ subunit of ENaC that delete their 
cytoplasmic C termini (Shimkets et al. 1994, Hansson et al. 1995) 
 
The phenotype expressed by the dexamethasone programmed offspring (low-renin 
low aldosterone type hypertension, associated with hypokalemia) might therefore 
result from one of the following three possibilities: 
 
1.) There is reduced renal 11β-HSD2 enzyme activity (similar to the 
syndrome of apparent mineralocorticoid excess). 
2.) There is an increase in circulating glycerrhetinic acid-like factors 
(GALFs) leading to inhibition of renal 11β-HSD2 enzyme activity. 
3.) There is an increase in cortisol or a similar mineralocorticoid-active 
steroid or factor in the dexamethasone programmed offspring. 
 
We contend that either the first or second possibility is more likely because, as 
explored later in this chapter, this phenotype was associated with increased 
sensitivity to exogenous glucocorticoids, indicating that the renal 11β-HSD2 enzyme 
barrier is attenuated. The present chapter therefore explores the effect of prenatal 
dexamethasone exposure on expression of 11β-HSD2 and other mediators of 











THE EFFECT OF PRENATAL DEXAMETHASONE TREATMENT ON 
RENAL 11β-HSD1 and 11β-HSD2  
 
Renal mRNA expression of 11β-HSD1 and 11β-HSD2 was compared in 1 week and 
9 months old offspring of dams that received dexamethasone or vehicle during the 
last week of pregnancy. Antenatal dexamethasone was associated with a marked 
reduction in renal expression of 11β-HSD2 mRNA. This decrease was seen at one 
week of age, and persisted into adulthood (decrease of 36%, p=0.04 and decrease of 
45%, p=0.04 in 1 week old and 9 months old offspring respectively). The decrease in 
11β-HSD2 mRNA was accompanied by a parallel reduction (37%) in 11β-HSD2 
enzyme activity (DEX, 4.41±0.36 protein; Control 2.76± 0.21 pmol product/ min/ 
mg; p=0.0015). 
 
In contrast, prenatal exposure to dexamethasone had no significant effect on renal 
11β-HSD1 mRNA expression compared to controls (p=0.3 and p=0.2 at 1 week and 
9 months respectively). The absence of significant effect of prenatal dexamethasone 
on renal expression of 11β-HSD1 was in contrast to liver 11β-HSD1, which had been 
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found to be upregulated after prenatal dexamethasone administration, at least in 
marmosets (Nyirenda et al. 2009)  
 
It is not known if prenatal dexamethasone has a direct or indirect effect in 
‘programming’ the renal expression of 11β-HSD2. However, we note that the 
expression of 11β-HSD2 in the liver and adrenals was not significantly altered by 
prenatal dexamethasone administration (p= 0.88 and p= 0.89 respectively).  This 
suggests that the ‘programming’ of this down-regulation of 11β-HSD2 expression 
observed in the kidney involves tissue-specific factors that influence the long-term 








Fig 4-1 Effect of prenatal dexamethasone on renal mRNA expression of 11β-HSD1, 
11β-HSD2 and renal 11β-HSD2 enzyme activity. 
 
Renal 11β-HSD2 activity was measured in 9 months old offspring of dams that 
received dexamethasone (DEX) or control during the last week of pregnancy.  
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THE EFFECT OF EXOGENOUS CORTISOL ON RENAL ELECTROLYTE 
HANDLING 
 
Decreased 11β-HSD2 activity in the kidney would increase glucocorticoid access to 
MR and thereby promote sodium reabsorption and potassium excretion. To test 
whether the alteration in 11β-HSD2 activity described above was functionally 
important, we examined urine sodium and potassium concentrations in dex- treated 
and control animals after exogenous administration of cortisol. Cortisol will be easily 
metabolized in presence of adequate 11β-HSD2 but not if 11β-HSD2 activity is 
critically reduced.  
 
In our metabolic cage experiments, baseline urine electrolytes (sodium and 
electrolytes) were measured over a 24 hour period. After the administration of a 
subcutaneous injection of cortisol (0.5 mg/kg), the urine electrolytes were measured 
for a further 24 hour period. 
 
Rats prenatally exposed to prenatal dexamethasone showed a significantly greater 
fall in the ratio of sodium to potassium in the urine after cortisol administration, 
consistent with increased mineralocorticoid action from an attenuated 11β-HSD 2 




In accord with increased sodium (and water) reabsorption with increased 
mineralocorticoid activity, we observed that cortisol administration was associated 
with a significant decrease in urinary sodium concentration (p=0.006). This increased 
sodium reabsorption (and hence decreased urinary sodium concentration observed) 
would suggest that this degree of 11β-HSD2 enzyme activity reduction (of 36%) 
allows exogenous cortisol at the dose used (0.5mg/kg) to increase mineralocorticoid 
activity leading to increased renal sodium and water reabsorption, a key mechanism 
in the development of chronic higher blood pressures in physiological models. 
 
Although we expected significant kalliuresis (and increased urinary potassium 
excretion) after the administration of cortisol in the dexamethasone-treated animals, 
we did not observe this to be so (Table 4-3). This could likely be due to that the 
sodium content in the diet used (0.3% sodium chloride) was insufficient to allow 
marked kalliuresis to be expressed. 
 
It is also noteworthy that the baseline urine potassium between controls and 
dexamethasone-treated animals were similar, despite the reported decreased 11β-
HSD2 enzyme activity and higher mineralocorticoid activity which would result in 
kalliuresis. This is likely due to the lower plasma potassium levels in the 
dexamethasone-treated animals compared to the controls (DEX, 4.5 mmol/L; 





In our metabolic cage experiments, there were no significant differences in 24-hour 
urine volume between the dexamethasone-treated group and controls at baseline, and 
after the administration of cortisol. We also did not detect any differences in 
bodyweight in the dexamethasone-treated and controls, both at baseline and at the 
end of the experiment. 
 
 












Table 4-1 Effect of exogenous cortisol on urinary sodium/potassium ratio in 9 







Group Baseline urinary sodium 
concentration mmol/L 
Urine sodium concentration 










Table 4-2 Effect of exogenous cortisol on urinary sodium concentration in 9 months 













Group Baseline urinary potassium 
concentration mmol/L 
Urine potassium concentration 










Table 4-3 Effect of exogenous cortisol on urinary potassium concentration in 9 
















THE EFFECT OF DEXAMETHASONE ON RENAL EXPRESSION OF THE 
MINERALOCORTICOID RECEPTOR AND GLUCOCORTICOID 
RECEPTOR 
 
Previous studies have implicated MR and GR as important programming targets in 
various organs. In rodents, prenatal dexamethasone was associated with an increased 
expression of GR in the liver, possibly crucial in the upregulation Pck2, (a rate-
limiting gluconeogenic enzyme) observed in the periportal region of the liver. 
However, we did not detect any increase (or decrease) in GR mRNA expression in 
the 1 week old or 9 months old rat kidneys. Similarly, we did not detect any 












































































THE EFFECT OF DEXAMETHASONE ON RENAL EXPRESSION OF THE 
EPITHELIAL SODIUM CHANNEL (ENAC) SERUM- AND 
GLUCOCORTICOID-REGULATED KINASE (SGK1) 
 
Sgk1 is an enzyme downstream of activated MR in the renin-aldosterone pathway 
which mediates the action of aldosterone in the distal renal tubular cell, leading to 
increased sodium reabsorption via ENaC. We hypothesized that Sgk1 mRNA 
expression in our rat model would be altered (upregulated) by the increased 
mineralocorticoid activation from reduced 11β-HSD2 expression in the kidney. 
However, renal Sgk1 expression was similar between rats that were exposed to 
dexamethasone prenatally and control animals (p=.42 and 0.27 at 1 week and 9 
months respectively). The explanation for this is unclear, but it is possible that an 
enzyme other than Sgk1 may be operative in mediating the actions of activated MR. 
Indeed, in knockout mice lacking Sgk1, the predicted phenotype of salt-losing 
hypotension was not observed, indicating the existence of other downstream 
mediators of activated MR (Wulff et al. 2002). 
 
Similarly, mRNAexpression of the various subunits of ENaC was not found to be 
statistically different between the prenatal dexamethasone treatment group and their 
control litter-mates. Although the levels of relative expression for all three subunits 
of ENaC (especially ENACα) tended towards an upward trend in 1 week DEX-
treated animals (p=0.05), none of these changes quite reached statistical significance. 
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Moreover, the tendency for ENACα to be higher in the dexamethasone-treated 
animals did not persist in adult (9 months) offspring. 
 
Nuclear MR activation leads to the subsequent transcription of various genes, 
including ENACs, which are crucial for transepithelial sodium transport. We note 
that ENaCs activity however, is not critically regulated at the mRNA level: it is the 
post-transcriptional modifications and transport and insertion of ENaC subunits into 










Fig 4-3 Effect of prenatal dexamethasone on the renal mRNA expression of ENaC 
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IMMUNOHISTOCHEMISTRY AND HISTOLOGY 
 
We employed immunohistochemistry to localize 11β-HSD2 expression within the 
kidney. Previous immunohistochemical studies in
 
human kidney showed strong 11β-
HSD2 immunoreactivity in the cortical
 
distal convoluted tubules and collecting 
ducts. Strong staining was also
 
observed in medullary tubules, which had the 
appearance of collecting ducts
 
and the thick ascending limb of Henle's loop. This is 
consistent with the findings by other studies (Krozowski et al. 1995). Thus 11β-
HSD2 co-localizes with the mineralocorticoid receptor in the distal
 
nephron where it 
allows aldosterone to occupy its physiological receptor.  
 
Our results were consistent with these findings: 11β-HSD2 was selectively expressed 
in the DCT (site of mineralocorticoid action), with no appreciable amounts of 11β-
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PCT Proximal tubule 




In dexamethasone-treated rats, immunohistochemistry showed strong 11β-HSD2 
immunoreactivity in the cortical
 
distal convoluted tubules and collecting ducts. In 
addition, we did not detect differences in glomerular size (DEX, 10 190± 723 µm²; 
control, 10 370± 752 µm²; p=0.86) or numbers ( DEX, 8.9± 2.1; control 9.4± 1.3 
glomeruli per field under 25x magnification; p= 0.82) in  dexamethasone-treated 
adult offspring at 9 months of age as compared to their control litter-mates (n=9 per 
group  
 
We speculate that this may, at least in our model, be due to the fact that the 
normalized kidney weight (kidney weights normalized to bodyweight) was not 
different between the 2 groups. Since total body circulating blood volume is 
dependent on body weight, the total body circulating blood volume is proportionally 
reduced in the dexamethasone-treated animals, leading to normal, and not 
hyperfiltration of the glomeruli. This is consistent with the lack of glomerular 
hypertrophy and equal glomeruli numbers observed between the 2 groups at 9 
months. At 9 months, the dexamethasone-treated animals had caught up in terms of 
body weight and absolute kidney weight (see Table 3-4 in Chapter 3), and there were 
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Our study demonstrates that hypertension programmed by prenatal overexposure to 
glucocorticoids is associated with a permanent decrease in renal 11β-HSD2 mRNA 
expression and activity, without any effect on expression of GR, MR and 11β-HSD1 
mRNAs. The reduction in renal 11β-HSD2 occurs in association with increased circulating 
glucocorticoids, as we have previously shown that DEX programmed rats have high plasma 
corticosterone concentrations [Levitt NS et al 1996, Nyirenda et al 1998].  
 
11β-HSD2 plays a critical role in the kidney, protecting MR from activation by 
glucocorticoids, and attenuated 11β-HSD2 activity might therefore allow illicit stimulation 
of MR by endogenous cortisol (or corticosterone in rodents), leading to plasma volume 
expansion due excessive sodium retention. Indeed, hypertension in DEX-exposed rats was 
accompanied by hypokalemia and suppression of renin and aldosterone production.  
 
Moreover, exogenous glucocorticoid administration elicited an acute mineralocorticoid 
response only in programmed rats, whilst treating the animals with spironolactone, an MR 
antagonist, eliminated the difference in blood pressure between the DEX group and control 
animals. In this respect, this model recapitulates SAME which traditionally occurs in patients 
with inactivating mutations in the 11β-HSD2 gene or after ingestion of liquorice, a naturally 
occurring inhibitor of 11β-HSD2 enzyme (Mune et al 1995, Stewart 1988). 
 
In our rat model, prenatal DEX caused approximately 45% reduction in renal 11β-HSD2 
mRNA and activity. This reduction is quantitatively similar to that seen in humans with 
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heterozygous mutations that induce salient features of the SAME (Li et al 1997)]. Moreover, 
polymorphisms in the 11β-HSD2 gene have been associated with essential hypertension in 
some populations, although this has not been consistently reproduced (Williams et al 2005, 
Brand et al 1998, Watson 1996). 
 
The syndrome of apparent mineralocorticoid excess is inherited in an autosomal 
recessive fashion, with patients with this syndrome presenting early in childhood or 
adolescence (Lifton, Gharavi and Geller 2001, Stewart et al. 1996). However, there 
are also reports that parents of these patients (heterozygotes) can display features of 
SAME (low-renin low-aldosterone hypertension with hypokalemia), suggesting a 
gene dosage effect.  
 
Similarly, inhibition of 11β-HSD2  activity with liquorice results in dose-dependent 
changes in blood pressure (Funder et al. 1988, Edwards et al. 1988, Stewart et al. 
1987), (White, Mune and Agarwal 1997, Monder et al. 1989). It is therefore likely 
that the modest of reduction of 11β-HSD2 activity seen in dexamethasone-
programmed rats contributes, at least in part, to the hypertension observed.  
 
Our data showing that features of SAME can be provoked by high salt feeding in 
young programmed rats suggest that heterozygous individuals with11β-HSD2 
mutation (who have subclinical deficiency of the enzyme) might have susceptibility 
to develop hypertension when exposed to physiological stressors (such as high sat 




Since the decrease in renal 11β-HSD2 mRNA expression in DEX-exposed rats was observed 
as early as 1 week of age, it is likely that this change was primary rather than secondary to 
other mechanisms, such as changes in blood pressure, especially important as the 
decrease in 11β-HSD2 in may be a compensatory response to the hypotension seen in 
this model when measured by radiotelemetry in “stress-free” environments.  
 
Indeed, at a young age (2 months), there was no significant difference in blood pressure 
between young DEX-exposed and control rats under standard dietary conditions (although 
we do not rule out the possibility that important small differences in blood pressure may 
remain undetected). Nevertheless, offspring of dams that received DEX displayed exquisite 
sensitivity to high salt feeding, which brought out the hypertensive phenotype and provoked 
hypokalemia, suggesting that the decrease in renal 11β-HSD2 activity was functionally 
significant from an early age.  
 
Taken together, our data indicate that prenatal DEX programs reduced 11β-HSD2 and 
increased salt sensitivity from birth. Children with IUGR have high plasma cortisol-to-
cortisone ratio, indicative of reduced 11β-HSD2 activity (Houang et al 1989) . Since the 
kidney is the major site of 11β-HSD2 production postnatally (Whitworth et al 1989), it is 
tempting to speculate that reduced renal 11β-HSD2 expression might explain, at least in part, 
the association between low birth weight and later susceptibility to hypertension.  
 
As in humans, although the deficit in 11β-HSD2 expression was seen early, the increase in 
blood pressure in our DEX programmed rats only become apparent upon increasing dietary 
salt content, and with aging, presumably as a result of the additive effects of subsequent 
environmental factors. This is consistent with recent proposals that aging amplifies the effect 
of low birth weight on blood pressure (Huxley et al 2000, Davies 2006). 
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Other studies have suggested reduction in nephron number as a mechanism of 
prenatal programming of hypertension (Brenner, Garcia and Anderson 1988). 
Optimal quantification of nephron size would include the length and size of the distal 
nephron. In this respect, our studies did not achieve detailed estimates of renal mass 
and nephron size/number. Based on our measurements, we were not able to detect 
lower glomerular numbers or glomerular hypertrophy in the dexamethasone-treated 
adults. This lack of changes seen in the glomerular size and number departs from the 
observations in other models, where structural kidney changes are observed.  
 
One factor may be because the programming of structural changes in the kidney 
changes is dependent on the dose of glucocorticoids used. Baum et al have used 
intraperitoneal dexamethasone at a dose of 200 mcg/kg /day dexamethasone in their 
programming model (double that used in our model) and found a modest 20% 
decrease in the glomerular number using unbiased stereomicroscopic methods. In 
their model, with these additional changes in glomerular numbers, hypertension was 
seen in their 2 months old animals, departing somewhat from our observations.  
Further experiments in glomerular apoptosis, collagen deposition and albuminuria 
should help confirm whether other important changes in renal structure and 
physiology relevant in fetal programming models are present in our model. 
 
Previous studies have indicated that glucocorticoid (or stress) during pregnancy 
programs coordinated changes in whole organism physiology, perhaps reflecting 
fetal adaptations to increase chances of surviving the projected extrauterine 
environment. These adaptations may, at least in part, be mediated by tissue specific 
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changes in glucocorticoid action. For example, dexamethasone-programming in the 
rat alters GR, MR and 11β-HSD21 in various tissues (Welberg and Seckl 2001, 
Levitt et al. 1996, Seckl 2004, Edwards et al. 1996, Seckl et al. 1995). Similarly, 
prenatal glucocorticoid excess in marmosets induced permanent increases in liver 
GR and/or 11β-HSD1 expression in key metabolic tissues, which might contribute to 
the pathogenesis of hyperglycaemia (Nyirenda et al 2009).  
 
Interesting, in the rat kidney, only 11β-HSD2 expression was altered by prenatal 
dexamethasone treatment, with other targets (such as GR, MR or 11β-HSD1) 
unchanged. Our study therefore identifies 11β-HSD2 as the key programming target 
gene in hypertension. The mechanisms by which dexamethasone induces permanent 
changes in 11β-HSD2 expression are unclear, but these may involve either a direct 
effect on the 11β-HSD2 gene itself, or secondarily by regulating key transcriptional 
factor(s).  
 
One potential direct effect might involve epigenetic modification. The 11β-HSD2  
promoter has CpG islands (Alikhani-Koopaei et al. 2004), and  increased methylation 
of the CpG islands have been shown to result in decreased expression of 11β-HSD2  
mRNA. Prenatal environmental insults (such as maternal undernutrition) during 
critical periods of development have been shown to affect methylation status of 
genes (including GR), and it is therefore plausible to speculate that fetal exposure to 
glucocorticoid excess might have a similar epigenetic effect. Future experiments and 
knowledge of 11β-HSD2 regulation (e.g., promoter methylation) will help with 
unraveling the exact mechanism involved. 
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Downstream signalling components of the mineralocorticoid signalling components 
in the kidney include SGK-1 and ENAC. Patients with Liddle’s syndrome, a 
monogenic disease in which ENAC are not degraded via ubiquination due to a 
mutation involving the recognition site on ENAC by Nedd4-2, develop low-renin, 
low-aldosterone, hypokalemia and hypertension, features similar to those observed in 
our programming model. It was thus important to measure the expression of ENAC 
subunits and SGK-1, as it remained a possibility that dexamethasone programming 
per se might upregulate ENAC and SGK-1, apart from the usual upstream activation 
by MR. However no statistically significant upregulation of ENAC and SGK-1 gene 
expression was found experimentally in our programmed animals at age 1 week or 9 
months.  
 
Ideally, it would be important to investigate apical ENAC abundance and activity as 
well as SGK phosphorylation states in our programming model to confirm that 
downstream targets of MR are indeed upregulated; experiments to document 
increased water reabsorption in the distal tubules using in vivo microperfusion 
techniques would also strongly support our hypothesis that water reabsorption in the 
aldosterone-sensitive distal tubule is important in our programming model.  
 
We note, however, that the regulation of ENAC by 11β-HSD2, is not straightforward 
(Bailey et al. 2008) . In the 11β- HSD2 null mice, although sodium retention with 
increased ENAC activity was observed initially, by 80 days old, these mice were 
volume contracted, not expanded as expected, and the increased ENAC activity was 
abolished. Instead there appeared to be a switch in the mechanism of hypertension 
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from increased sodium and water retention to increased vasoconstriction with 
adrenergic blockade relieving the hypertension in the older mice.  
 
Other limitations also affect the interpretation of our data. In our experiments, only 
male offspring were investigated and gender-differences in the programming of 
hypertension have been observed broadly across many species; female offspring thus 
may have different mechanisms of hypertension programming. Additionally, it is 
unknown whether the high salt diet itself affects 11β-HSD2 mRNA expression. It is 
also important to establish if microalbuminuria, a strong predictor of cardiovascular 
risk, is increased in our programming model.  
 
Finally, aside from the kidney, 11β-HSD2 is also expressed in a number of organs, 
notably the heart and vasculature where it may play an important role to regulate 
blood pressure. It is therefore important to investigate whether prenatal 
dexamethasone affects expression of 11β-HSD2 mRNA and activity in these tissues, 
in particular cardiovascular structures such as the blood vessels and the myocardium, 
and whether this contributes to the hypertensive phenotype. 
 
Despite the limitations mentioned, our data indicate that renal 11β-HSD2 is an 
important candidate gene in fetal programming of hypertension and provides a novel 
mechanism for fetal origins of adult salt-sensitive hypertension. If extrapolated to humans, 
these data suggest that programmed hypertension may be amenable to measures to reduce 
features of mild SAME such as blockade of MR or its downstream targets and that such 








In this chapter, we showed that prenatal dexamethasone exposure reduces renal 
expression 11β-HSD2. This decrease in 11β-HSD2 expression was present in young 
(1 week old) offspring, and persisted till adulthood. Not surprisingly, 11β-HSD2 
enzyme activity, as measured in an in vitro assay was significantly reduced. This 
modest degree in renal 11β-HSD2 activity reduction appears to be physiologically 
relevant: the administration of exogenous cortisol, acting as a mineralocorticoid, 
induced a significant decrease in the sodium: potassium ratio in the 24-hour urine 
collection. 
 
The decrease in 11β-HSD2 activity likely plays an important pathogenic role in the 
higher blood pressures observed in dexamethasone-programmed offspring. Similar 
findings by other investigators employing different models of programming highlight 
the important general role that 11β-HSD2 (and the mineralocorticoid signalling 
pathway) may play in mediating hypertension in fetal programming (Bertram et al 










EXCESSIVE PRENATAL GLUCOCORTICOID EXPOSURE 
PROGRAMMES OFFSPRING ERYTHROPOEITIN AND INCREASES RED 






Poiseuille’s Law states the relationship between blood pressure and viscosity: the 
higher the viscosity, the higher the blood pressure.This raises the interesting 
possibility that the hypertension observed in the dexamethasone- programmed 
offspring could be in part contributed by yet another renal mechanism - increased 
erythropoietin production with increases in red cell mass, leading to subsequent 
hyperviscosity. In the previous chapters, we investigated the effects of prenatal 
dexamethasone on blood pressure, mediated through alteration in renal tubular 11β-
HSD2 expression. In this chapter, we hypothesized that prenatal glucocorticoid 







Erythropoietin is the key hormone that stimulates hematopoietic stem cells in the 
bone marrow, liver and spleen, to increase erythropoeisis. During development, 
erythropoietin synthesis takes place in fetal liver and kidney, but postnatally the 
kidney is the main organ for production of erythropoietin (Beru et al. 1986). 
 
The regulation of erythropoietin in the kidney has been investigated and summarized 
previously (Goldberg, Dunning and Bunn 1988). Tissue hypoxia critically induces 
erythropoietin production in chronic anemia. At the molecular level, erythropoietin 
production is determined by gene transcriptional activity. The erythropoietin gene 
has a 3
’ 
enhancer that contains a hypoxic- responsive element (HRE). The hypoxia 
inducible factors (HIFs), which include HIFα and HIFβ subunits, play an important 
regulatory role in response to tissue hypoxia. HIFs interact with other transcriptional 
factors such as HNF4α, GATA and Sp1 at the enhancer site, allowing for the 
hypoxia-driven induction of erythropoietin gene expression (Ebert and Bunn 1999).  
 
Hepatocyte nuclear factor 4 alpha (HNF4α) is constitutively expressed in the sites of 
erythropoietin production (the adult kidney and the fetal liver). HNF4α  binds to the 
erythropoietin (EPO) 3
’
 enhancer site which lies next to the HIF-binding site 
(Blanchard et al. 1992) . HIF and HNF4α  interact together with transcription factors 
like P300, form a stable multifactorial complex at the 3
’ 
enhancer and reinforces the 
promoter-enhanced contact, leading to the greater transcriptional activity and 




Recently, prenatal dexamethasone exposure was found to significantly elevate 
hepatic HNF4α  mRNA expression in both fetal and adult offspring (Nyirenda et al. 
2006). This increase resulted from increased expression of isoforms derived from the 
P1 HNF4α promoter. In contrast, isoforms derived from the P2 promoter were 
markedly suppressed by dexamethasone. This increase in HNF4α mRNA expression 
was postulated to mediate the effects of prenatal dexamethasone in programming 
hyperglycemia. 
 
Given the possibility that prenatal dexamethasone may also, via similar molecular 
mechanisms, up regulate HNF4α expression in the kidney, we also investigated the 
effects of prenatal dexamethasone on renal HNF4α.  
The possibility that renal erythropoietin production may be programmed by prenatal 
dexamethasone is an exciting one. Beyond the possible effect on blood pressure,  
increased erythropoietin has been independently shown to increased cardiovascular 
risk, and thus provides a novel mechanism to explain the higher cardiovascular  and 

















EFFECT OF PRENATAL DEXAMETHASONE ON RENAL AND HEPATIC 
ERYTHROPOEITIN EXPRESSION  
 
EPO mRNA expression was measured in the offspring in the neonatal period at the 
age of 1 week, and in the adult offspring at 9 months of age. At 1 week, offspring of 
dams that received dexamethasone in the last week of gestation had significantly 
higher EPO mRNA expression compared to those that were born to control mothers 
(increase of 2.4 fold; p=0.01). This trend of higher EPO mRNA expression was also 
observed in the 9 month old cohort. Again, the dexamethasone-treated offspring had 
higher EPO mRNA expression compared to their control offspring (increase of 1.9 






Fig 5-1 Effect of prenatal dexamethasone on EPO mRNA expression in 1 week old 






To confirm that the increase in renal EPO mRNA expression was functionally 
important we measured the concentration of EPO in plasma in 9 month old animals. 
Indeed, prenatal exposure to dexamethasone was associated with a significant 
increase in circulating plasma EPO levels (increase of 1.6 fold; p=0.04). As EPO is 
thought to be regulated primarily at the level of gene transcription (Wiesener et al. 
1998), the increase in plasma EPO concentration is consistent with the increase 





Fig 5-2 Effect of prenatal dexamethasone on plasma EPO concentration in 9 month 






The fetal liver is the other key site of EPO production, although postnatally only the 
kidney is the main source of EPO. In order to get better understanding of the effect of 
glucocorticoids on EPO expression, we studied the effect of dexamethasone on 
hepatic expression of EPO in the liver, at embryonic day 21 (E21) and in adulthood. 
EPO was readily detected in fetal liver, and, as in the kidney, dexamethasone 
treatment caused a significant increase EPO mRNA expression at E21 (increase of 
2.2 fold; p=0.03).  
 
 
Fig 5-3 Effect of prenatal dexamethasone on hepatic EPO mRNA expression at E21. 
n=6 per group. 
 
In contrast, we did not detect appreciable amounts of EPO mRNA in the adult livers 
of either control or dexamethasone-treated group. This is consistent with previous 







THE EFFECT OF PRENATAL DEXAMETHASONE ON RENAL HNF4α 
ISOFORM EXPRESSION 
 
Previous work in the laboratory had shown that prenatal dexamethasone treatment 
permanently increases expression of HNF4α in the liver. Specifically, 
dexamethasone increased expression of the isoforms derived from the P1 promoter, 
while those driven by the P2 promoter were significantly suppressed. In order to 
determine whether prenatal dexamethasone exposure had similar effects on 
expression of HNF4α in the kidney, we measured expression of these isoforms in 
kidneys of rats that were born to mothers that received dexamethasone or vehicle 
during the last week of pregnancy.  Offspring of dams that received dexamethasone 
during gestation had significantly higher renal HNF4α mRNA expression than 
offspring of control dams (increase of 51%, p=0.03). Importantly, the increase in 
HNF4α mRNA was observed in one week old offspring (increase of 64%, p=0.01). 
This suggests that transient prenatal dexamethasone treatment of maternal dams in 
the third week of gestation upregulates the expression of renal HNF4α mRNA 
expression in the young (1 week old) offspring, and this effect (upregulation renal 
HNF4α mRNA expression) persists on into adulthood. This is similar to what has 







Fig 5-4 Effect of prenatal dexamethasone on renal HNF4α mRNA expression. 
*=p<0.05. n=6 per group. 
 
However, when we probed for specific isoforms, we observed that all the HNF4α 
isoforms in the kidney appeared to derive from the P1 promoter, with no appreciable 
P2 transcripts detected, both in control or dexamethasone -exposed rats. This 
 
136 




























EFFECT OF PRENATAL DEXAMETHASONE ON TRANSCRIPTIONAL 
FACTORS INVOLVED IN EPO REGULATION 
 
We also examined the effect of prenatal dexamethasone treatment on renal 
expression of other transcription factors that are involved in the regulation of EPO 
synthesis from the kidney. These include hypoxia-inducible factor 1, alpha subunit 
(HIF1α), hypoxia-inducible factor 2, alpha subunit (HIF2α)  aryl hydrocarbon 
receptor nuclear translocator (ARNT) and GATA binding protein 2 (GATA2). These 
transcriptional factors, especially HIFs, form a transcriptional complex with HNF4α 
at the EPO 3’enhancer and act synergistically to recruit other transcriptional 
coactivators. 
 
There were no significant differences between offspring of dexamethasone -treated 
dams and control animals in renal expression of HIF1α, HIF2α, ARNT or GATA2 








































































































Fig 5-5 The effect of prenatal dexamethasone on transcriptional regulators of EPO. 
n=6 per group at 1 week (Figure A) and 9 months (Figure B).  
 
Thus, of all the transcriptional regulators of EPO transcription, only renal HNF4α 
(P1-driven transcript) was upregulation by prenatal dexamethasone. This 







EFFECT OF PRENATAL DEXAMETHASONE ON BLOOD COUNT IN 
ADULT OFFSPRING 
 
Since EPO is the main regulator of erythropoiesis, we next examined whether the 
increase in EPO synthesis following prenatal exposure to dexamethasone was 
associated with changes in red cell mass. The adult offspring of dams that were 
treated with dexamethasone during the last week of pregnancy had a significant 
increase in the number of circulating red blood cells (increase of 7%; p=0.02), 
hematocrit (increase of 8% p=0.004) and hemoglobin concentration (increase of 7%; 
p=0.02). This was accompanied by an increased reticulocyte count (increase of 10%; 
p=0.04). There were no differences in mean corpuscular volume (MCV), mean 
corpuscular hemoglobin (MCH) or mean corpuscular hemoglobin concentration 
(MCHC) between offspring of dexamethasone -treated dams and controls.  
 
Prenatal dexamethasone treatment also resulted in the white blood cell (WBC) and 










 Control DEX P value 
WBC (10
9
/L) 8.7±0.8 10.6±0.9 0.11 
RBC (10
12
/L) 8.8±0.2 9.4±0.1* 0.02 
RET (10
9
/L) 235.7±5.6 258.2±8.8* 0.04 
HCT (%) 46.7±0.7 50.0±0.5** 0.004 
HGB (g/dL) 16.2±0.2 17.3±0.2* 0.02 
MCV (fL) 52.2±0.3 52.9±0.5 0.13 
MCH (pg) 18.0±0.1 18.2±0.2 0.58 
MCHC (g/dL) 34.57±0.13 34.35±0.14 0.35 
PLT (10
9
/L) 476.3±82.6 620.7±56.0 0.17 
 
 
Table 5-1 Blood cell indices. *=p<0.05; **=p<0.01. n=9 animals per group. 
 
HCT, hematocrit; HGB, hemoglobin; MCH, mean corpuscular hemoglobin; MCHC, 
mean corpuscular hemoglobin concentration; MCV, mean corpuscular volume; PLT, 













In this chapter, we investigated the effect of prenatal dexamethasone on 
erythropoeisis. Prenatal exposure to dexamethasone was also associated with 
increased expression of EPO mRNA in the kidney and fetal liver- the key sites of 
erythropoietin production. The increase of EPO mRNA was accompanied by a 
similar increase in plasma EPO concentrations in adult offspring. Although we 
hypothesized that the increase in systolic blood pressure could in part be mediated by 
increased plasma viscosity (by Poiseuille’s Law), ultimately, we find that the 
absolute increase in hematocrit (by a meager 6%), although statistically significant, is 
unlikely to contribute as a factor to the increase in blood pressure observed through 
changes in viscosity. Nonetheless, a raised plasma erythropoietin per se has been 
associated with an increase in cardiovascular risk and mortality. Hence, it will be of 
clinical interest to investigate if similar changes in plasma erythropoietin are 
observed in low birth weight humans. 
 
Interestingly, although prenatal dexamethasone permanently elevates hepatic 
expression of P1 HNF4α transcripts (Nyirenda et al. 2006) in the adult livers, (a 
finding which we replicated in our experiments),  EPO is not detected in the liver 
postnatally, and over expression of HNF4α mRNA per se was not sufficient to 




EPO is not stored preformed, and therefore any change in plasma EPO concentration 
results primarily from a change in transcription of the gene (Ebert and Bunn 1999). 
Although acute regulation of EPO transcription, mediated via HIF, has been 
extensively studied (Semenza 2001), the mechanisms that control steady-state 
production of EPO necessary to maintain the physiological daily renewal of red 
blood cells are less clear (Fandrey 2004). Similarly, determinants of developmental 
and tissue-specific
 
expression of EPO are largely unknown.  
 
Most studies suggest that HIF requires cooperation with other transcription factors to 
regulate of EPO expression. In particular, HNF4α, which is constitutively expressed 
in fetal liver and adult kidney, the major sites of EPO production, contributes 
importantly to the physiologic regulation of the EPO gene.  
 
HNF4α binds adjacent to HIF binding-site in the mouse EPO 3’ enhancer where it 
functions synergistically with HIF1 through direct protein-protein interaction and by 
recruitment of transcriptional coactivators (Ebert and Bunn 1999, Ebert and Bunn 
1998). HNF4α expression in HeLa cells (which do not normally express HNF4α) 
confers hypoxic inducibility to an EPO reporter gene (Galson et al. 1995, Bunn et al. 
1998b, Bunn et al. 1998a).  
 
We examined several important transcriptional regulators of EPO, including HIF1α, 
HIF2α, ARNT, GATA2 and HNF4α.  Prenatal dexamethasone treatment caused a 
permanent elevation in renal HNF4α (P-1 driven transcripts), whilst expression of 
other pertinent transcription factors including HIF was unaltered. HNF4α thus 
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appears to play a causal role in mediating the constitutive increase in renal and fetal 
hepatic EPO expression observed.  
 
HNF4α may participate in the programming of hypertension yet another mechanism 
of action. Recently, Dagan et al have shown that the urinary angiotensin II / 
creatinine level in dexamethasone-programmed offspring is raised in pre-
hypertensive rats, even though the plasma angiotensinII level is no different from 
controls. The urine angiotensinII/creatinine ratio is a measure of the renally produced 
and secreted angiotensin II, and the authors suggested the intriguing possibility that 
luminal angiotensin II may be involved in the perpetuation of hypertension in the 
dexamethasone-programmed rat model of hypertension (Dagan et al 2010). 
Interestingly, HNF4α is known to be an important transcriptional regulator of renal 
angiotensinogen (which is the precursor of angiotensin II) and is co-localized with 
angiotensinogen in the proximal renal tubule. This possibility that HNF4α could be 
responsible for the raised renal production of angiotensin II observed in this model. 
 
Here we demonstrate, for the first time, that overexposure to glucocorticoids during 
late gestation causes a lifelong increase in RBC mass in the rat. The other blood cell 
populations, such as white blood cells and platelets, were unaltered. The elevation in 
RBC count was associated with increased number of circulating reticulocytes and 
significant upregulation of mRNA expression and plasma concentration of EPO, the 
major regulator erythropoiesis, indicating that the increase in RBC mass resulted 
from enhanced production, rather than prolonged survival of RBCs. The increase in 
circulating EPO concentration and the resultant change in RBC mass following 
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prenatal exposure to dexamethasone is therefore likely to be mediated by enhanced 
EPO production from the kidney (in adults). 
 
There are, however, several limitations of this work. Firstly, it needs to be 
determined if the increased erythropoeisis observed is through enhanced basal, i.e. 
bone marrow erythropoeisis or increase in stress erythropoeisis, i.e. extramedullary 
spleen erythropoeisis. This could be determined by Ter119/CD71 flow cytometric 
profiles of the bone marrow and spleen.  Secondly, although our data show a 
correlation between HNF4α mRNA levels and EPO expression, this does not prove 
that HNF4α is causally responsible for increased EPO expression. Further 
experiments are needed, for instance to localize HNF4α protein within EPO-
producing cells, as well as chip analysis from renal extracts with the EPO promoter 
that unambiguously show increased binding of HNF4α to the EPO 
promoter/enhancer or an siRNA approach with knock-down of HNF4α in vivo to 
show that dexamethasone-treated animals no longer show increased EPO expression 
if their HNF4α expression is attenuated. Finally, dexamethasone programming may 
also cause possible changes in lung physiology e.g. affecting oxygenation. This 
would cause HIF proteins to be upregulated causing downstream increased 
production to be increased. Hence, measures of arterial blood oxygenation and HIF 






In conclusion, the long-term consequences of prenatal glucocorticoid excess on RBC 
in humans are unknown, but conditions associated with prenatal stress, such as 
intrauterine growth retardation or maternal diabetes, increase fetal/infant EPO 
concentrations and erythroblastosis (Lemery et al. 1994, Widness et al. 1981).  
Our data indicate that RBC mass can be permanently programmed by prenatal stress, 
and provide a novel mechanism for fetal origins of polycythemia and its associated 
























In this chapter, we explored the effect of prenatal dexamethasone on renal EPO and 
red cell mass. We also observed that parallel changes in HNF4α  upregulation. Only 
HNF4α P-1 driven transcripts were detected in the kidney and dexamethasone-
programmed offspring expressed higher levels of the transcripts than their control 
littermates. This upregulation of HNF4α transcripts may be functionally relevant, at 
least with regards to renal erythropoietin regulation. 
 
These findings indicate that HNF4α may play an important role in the molecular 




















Fetal programming is thought to subserve an important evolutionary function:  to 
better prepare the fetus for a predicted extrauterine environment.  However when 
there is a gross mismatch between projected ex utero and actual ex utero 
environment, such as with demographic transition due to increasing urbanization 
coupled with faster foods and a more sedentary lifestyle, this can result in adverse 
  Excessive fetal glucocorticoid (dexamethasone)  
Reduced renal 11βHSD2 expression and activity Increased salt-sensitivity 
Non-aldosterone 
(corticosterone/ cortisol) 
activation of MR  
Increased distal tubular  
mineralocorticoid/ ENAC activity 
Hypokalemia Impaired renal  
sodium excretion and 
excessive potassium excretion  
Increased cardiovascular 
and cerebrovacular risks 
Increased blood pressure  
Increased renal production of erythropoietin  
Increased plasma erythropoietin 
Increased red blood cell mass 
and haematocrit  
Increased plasma viscosity 
Figure 6-1 Proposed hypothesis and mechanisms by which excessive  
glucocorticoid (dexamethasone) might cause hypertension,  increased salt-
sensitivity and ultimately increased cardiovascular risk through key alterations in 
the kidney- namely, renal distal tubular 11βHSD2 activity and the renal production 
of erythropoietin.  
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outcome, such as deadly epidemics of hypertension, obesity and hyperglycemia 
(Gluckman, Hanson 2004). 
Compelling epidemiological evidence suggests that exposure to an adverse 
intrauterine environment, manifested by low-birth weight, is associated with 
cardiometabolic and behavioural disorders in adulthood. Previous work in our 
laboratory and others have shown in various animal models that this relationship can 
be mimicked by prenatal treatment with glucocorticoids ( Seckl 1997, Benediktsson 
et al. 1993, Seckl and Meaney 2006, Nyirenda et al. 1998, O'Regan et al. 
2004Koenen et al. 2002, Dodic et al. 1998, Levitt et al. 1996, Woods and Weeks 
2005). These observations have led to the concept of ‘fetal programming’ by 
glucocorticoids. The molecular mechanisms that underlie this relationship remain 
unclear, but are being extensively investigated using a number of experimental 
models.  
 
Studies in this thesis have confirmed that fetal over-exposure to glucocorticoids 
predisposes to hypertension in the affected male adult offspring. We investigated the 
hypothesis that the kidney plays a central role in the molecular pathogenesis of 
hypertension in the (dexamethasone) programming model using pregnant Wistar rats 
and male offspring. Better phenotyping and a better understanding of the 
pathogenesis of hypertension in programming would be useful in future studies for 
clinical assessment as well as in rational therapeutics.  
 
We established that renal 11β-HSD2 mRNA expression and activity were indeed 
decreased (by 45% and 36% respectively) in adult offspring. (Tang et al 2011) The 
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dexamethasone- programmed offspring also had lower plasma renin concentration, 
lower 24 hour urinary aldosterone levels and decreased plasma potassium- features 
consistently seen with the syndrome of apparent mineralocorticoid excess (whereby 
there is inactivating mutations in the 11β-HSD2 gene) as well as observed in licorice 
ingestion (due to inhibition of 11β-HSD2 enzyme by licorice). There was also a 
greater decrease in the urinary ratio of sodium to potassium ratio in response to an 
exogenous dose of cortisol (when compared to controls) - effects consistent with 
decreased 11β-HSD2 function in the renal tubules.  
 
Importantly, in a separate cohort of 1 week old neonates, the decrease in 11β-HSD2 
mRNA was already found to be present in the dexamethasone-programmed group, 
implying that the decrease in 11β-HSD2 was likely a primary change due to 
dexamethasone and not secondary to changes in blood pressure per se. It is 
particularly important to consider the work of O’Regan et al in this context (O’Regan 
2008), wherein it was found that programmed adult rats developed hypotension in 
the unstressed state (although most other investigators using the more “stressful” tail-
cuff methods have found hypertension).  
 
It thus remains a possibility that the downregulation of 11β-HSD2 observed could be 
a compensatory response to the hypotension observed (it cannot be ruled out that a 
small but important decrease in blood pressure could be present but undetected at 1 
week). Nonetheless, it has been pointed out by the authors (O’Regan et al) that these 
rats were hypotensive only when left undisturbed in a darkened room. Even minor 
“stressors” such as switching on the lights, or an observer entering the room caused 
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the blood pressures of the programmed rats to overshoot those of controls. Hence it is 
arguable whether under “normal” circumstances in the wild, where escape from 
predation is stressful and essential for survival; these ever-vigilant rats may indeed 
have higher blood pressures throughout the day. Additionally, we observed that the 
renin levels in the programmed rats were lower than controls, and indeed, in most 
cases of hypertension renin is lowered.    
 
In the offspring that were followed up to be 2 months of age in the younger cohort, it 
was found that systolic blood pressure in the dexamethasone-programmed group was 
not different from controls at 2 months of age. However, by stressing these younger 
animals with high salt diet, the dexamethasone-programmed group not only showed 
a higher rise in their systolic blood pressures, but they also developed plasma 
hypokalemia after high salt feeding. Interestingly, it has been observed that salt-
sensitivity may be associated with decreased renal 11β-HSD2 activity (Ferrari 2000). 
 
Our data indicate that prenatal dexamethasone programs reduced renal 11β-HSD2 
mRNA expression and increased salt sensitivity in the offspring. This increase in 
blood pressure only became apparent if dietary salt content increases significantly, or 
with aging, presumably as a result of the additive effects of subsequent 
environmental factors.  
 
The other novel finding in this thesis was the effect of prenatal dexamethasone on 
renal EPO and red cell mass. Previous data identified HNF4α, a key transcriptional 
regulator of EPO, as a key target of glucocorticoid programming in the liver 
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(Nyirenda 2006). In this thesis, we confirm that HNF4A expression is upregulated in 
the kidney where it was associated with increased erythropoietin and erythrocyte 
mass. The degree of red cell mass increase (a mere 6%) is unlikely to cause blood 
pressure increases. Nonetheless, future studies will be important to uncover the 
interactions between low birth weight, adaptive response to anemia and the possible 
contribution of higher erythropoietin levels and erythrocytes to hypertension, 
hyperviscosity and cardiovascular events (Tang et al, accepted for publication). As 
with 11β-HSD2, the underlying basis for the change in HNF4α expression is 
unknown, but epigenetics (e.g. DNA methylation and histone deacetylation) may be 
involved.  
 
In summary, the work of this thesis agrees with the hypothesis that reduced renal 11β-HSD2 
expression provides a novel mechanism for fetal origins of adult salt-sensitive hypertension 
in our model of programming. The higher erythropoietin levels seen likely does not 
participate in perpetuation of hypertension via hyperviscosity although it is clinically 
relevant to cardiovascular mortality. If extrapolated to humans, these data suggest that 
programmed hypertension may be amenable to measures to reduce features of mild SAME 
such as blockade of MR or its downstream targets and that such offspring may be 











Despite the advance in our understanding of the dexamethasone model of 
programming, many unanswered topics still remain. Further work will need to focus 
on dissecting the exact mechanism of how glucocorticoids programme renal 11β-
HSD2. The 11β-HSD2 promoter is known to contain numerous CpG sites. 
Methylation of these CpG sites are known to correlate with gene expression: the 
more the methylation, the less the gene expression (Alikhani-Koopaei et al. 2004). 
Numerous new techniques, including high through-put bisulfite sequencing (Laird 
2005, Gitan et al. 2002, Cokus et al. 2008) are rapidly evolving currently, presenting 
an opportune time to study if methylation patterns in the in utero environment change 
with glucocorticoid exposure, and if glucocorticoid exposure in early life influences 
the rate of methylation with aging. Intriguingly, there is already early evidence that 
methylation of the11β-HSD2 promoter can be programmed by maternal uterine 
artery ligation (Baserga 2010).  
 
Additionally, an extension of our work done will be to investigate if 11β-HSD2 in 
other important cardiovascular structures relevant to blood pressure control, such as 
the vascular and cardiac, is similarly down-regulated. Recent work has shown that 
11β-HSD2 may play an important role in limiting non-aldosterone activation of MR 
(by corticosterone) (Alzamora, Michea and Marusic 2000, Brown et al. 1996). 
Excessive MR activation may lead to vessel fibrosis, accelerated artherosclerosis and 
increased vascular oxidative stress, exacerbating endothelial dysfunction, 
hypertension, vascular and renal disease (Young, 2003).  
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It will also be important to investigate if the rise in systolic blood pressure is of 
pathophysiological significance in our model of programming. Here, using new 
techniques such as the optical coherence tomography (Brezinski 1996), direct 
assessment of vascular atherosclerosis (including the coronary vessels), for instance 
after high fat feeding, will be of value in future animal work. 
 
Finally it would be important to investigate if the effect of glucocorticoid 
programming on red blood cell mass is similarly observed in human populations. 
Animal studies in quantifying the erythropoietic and bone marrow response to 
anemia and hypoxia will also shed light on whether the findings of this thesis is of 
physiological significance with regards to the adaptative response to anemia, an 





















POSSIBLE IMPORTANCE OF 11 BETA-HYDROXYSTEROID 
DEHYDROGENASE TYPE 2 IN HUMAN HYPERTENSION 
 
Our experiments have shown that glucocorticoids in the form of dexamethasone 
programmed permanent decreases in 11β-HSD2 mRNA and activity in the adult 
offspring. The degree of reduction in 11β-HSD2 enzyme observed was associated 
with low-renin (low-aldosterone) type systolic hypertension. Moreover, younger 
dexamethasone-programmed offspring displayed salt-sensitive hypertension.  
 
25% of all human hypertension is of the low-renin type (Buhler et al. 1984). What is 
less clear is the proportion of low-aldosterone low-renin type hypertension in the 
population. This proportion of low-renin hypertension parallels the proportion of low 
birth weight infants distributed in the normal Gaussian manner. Future developments 
in developing accurate measures of renal 11β-HSD2 activity will help resolve the 
question if 11β-HSD2 play a significant role in human hypertension. 
 
If these physiological changes were similar in low birth weight humans (Simonetti 
2008), it would have important implications. Firstly, that children born in 
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impoverished societies (a substantial proportion of the world’s population) are at risk 
of developing (salt-sensitive) hypertension. Ironically, it is the children under poorer 
socioeconomic circumstances that are consuming the greatest amount of salt on a 
daily basis (Gray 2009). Moreover, as economies develop in third world countries, 
these children, already prone to developing hypertension, will be subjected to the 
industrialized lifestyles which will compound the possible epidemic in incidence of 
hypertension in these societies. Currently, the hypertension epidemics in India and 
China, the 2 most populous countries in the world, are possible consequences of 
thrusting industrialized lifestyles upon hypertension-prone formerly low birth weight 
babies in these societies. 
 
The current trend of excessive salt intake in almost all but the most primitive of 
societies will assume a greater importance in public health policy if the findings of 
our work are extrapolatable to humans. It will be important to test the hypothesis that 
decreasing the average consumption of salt will lead to a decrease in the incidence of 
hypertension and its consequences, although this will require further rigorous 












IMPLICATIONS FOR PERSONALIZED MEDICINE AND THERAPEUTICS 
 
One of the aims of medical genetics is accurately predicting of the risk of developing 
disease. Will it ever be possible to predict disease e.g. hypertension?  
 
As argued by Weatherall using beta-thalassemia as an example, even if a disease 
were purely genetic, there are still primary, secondary and tertiary genetic modifiers 
of phenotype (Weatherall 2001). The resultant permutations and combinations of the 
various modifying genes inherited make the concept of predicting phenotype using 
genotype look overly simplistic, at the very least. 
 
Our research shows that the in-utero environment is able to alter gene expression 
(11β-HSD2) and influence resultant offspring phenotype. This adds another layer of 
complexity in trying to predict phenotype- the epigenome. Indeed, for the case of 
hypertension, genes are thought to account only 20-60% the risk of developing 
hypertension; the environment playing a (probably) greater part than previously 
thought (Lifton 2001).  
 
Until we know exactly how the environment affects the expression of genes (e.g. 
through epigenome), we are far from accurately predicting disease risk. To make 
matters even more complex, epigenome has been observed to change over time. For 
instance, the epigenome of twins were found to diverge over the years, indicating the 
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possibility that the environment may play a crucial role in the rate of CpG 
methylation and other crucial epigenomic processes (Fraga 2005). All these suggest 
the near-impossibility of predictive testing given the myriad complexities of 
genotype-environment-genotype interactions. 
 
On the other hand, if research can clearly define the many factors in accounting for 
disease development, then it may just be possible in future to compute and accurately 
predict risk for each individual. Future research, especially in the field of epigenetics, 
























 Joint National Council (JNC) guideline on hypertension has singled out 
thiazide diuretics as a first line drug for hypertension treatment, other drugs such as 
ACE-inhibitors, beta-blockers, calcium channel blockers usually started if there are 
compelling indications (Chobanian et al. 2003).  
 
Our work in dexamethasone-programmed rats suggests that hypertension in these 
animals is due to increased mineralocorticoid receptor activation (by corticosterone 
in the face of decreased renal 11β-HSD2 activity) leading to low-renin type 
hypertension with hypokalemia. If this mechanistic finding is extrapolatable to 
humans, it is plausible that low birth weight (often recallable by patients) may be a 
compelling indication for use of mineralocorticoid receptor antagonists (such as 
spironolactone, eplerenone and amiloride) at an earlier stage of hypertension, leading 
to more rational therapeutics. 
 
In addition, hypokalemia provoked by the mineralocorticoid antagonists is an added 
advantage: potassium is known to be an independent risk of cardiovascular and 
stroke, two of the more feared complications of hypertension (Khaw and 
Barrettconnor 1987, Meneely and Battarbee 1976, Nordrehaug, Johannessen and 






IMPLICATIONS OF THE PROGRAMMING OF RED BLOOD CELL MASS 
 
We hypothesized that glucocorticoid programming might have salient effects on 
other physiological systems (e.g. hematological system). These coordinated changes 
in whole organism physiology would allow the offspring to better survive an adverse 
environment ex-utero.  
 
Our work showed that red cell mass, hemoglobin and hematocrit is increased in 
dexamethasone-programmed offspring, a novel finding. This work has important 
implications in providing mechanistic insights into how individuals have marked 
variable response to anemia.  
 
Millions of low birth weight infants in the third world suffer from anemia caused by 
malaria or hereditary diseases such as the thalassemias and sickle cell disease. 
Further study into the molecular basis on how programming might allow them to 
adapt and augment their response to anemia (e.g. via erythropoietin and HNF4α) 
could provide new pathways for rational treatment. 
 
On the other hand, raised hematocrit has been implicated in strokes and acute 
cardiovascular events. Hence, exploring the pathways regulating the hematopoietic 
response may yield fruitful therapeutic targets in reducing cardiovascular and stroke 







GLUCOCORTICOID PROGRAMMING: PROPOSING AN EXTENDED 
MODEL INVOLVING 11 BETA-HYDROXYSTEROID DEHYDROGENASES  
 
Dexamethasone programming in pregnant Wistar rats produces offspring with 
features of the metabolic syndrome, namely hypertension and hyperglycemia 
(Nyirenda 1998. O’Regan 2004). 
 
Glucocorticoids are important key metabolic regulators, at least in mammalian 
physiology. Previously, the role of the glucocorticoid receptor as a key programming 
target in various tissues has been comprehensively reviewed (Seckl 2004). What is 
emerging, unsurprisingly, is that the 11β-HSDs are also important programming 
target genes (see Figure 6-1). 
 
As mentioned in the earlier chapters, the enzymes 11β-HSD1 and 11β-HSD2 mediate 
intracellular glucocorticoid action. 11β-HSD1 amplifies intracellular glucocorticoid 
action by favoring the conversion of inactive cortisone to active cortisol (in humans). 
Transgenic mice model overexpressing 11β-HSD1 adipocyte cells, developed 
insulin-resistant glucose intolerance and other features of Cushing’s syndrome, even 
though plasma cortisol were not different from control animals (Masuzaki 2001). 
Recently, we have shown that in marmoset primates, dexamethasone given in late 
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gestation was associated with increased liver expression of 11β-HSD1 (Nyirenda 
2009). This local amplification of glucocorticoid action was associated with 
increased expression of PCK1, a rate-limiting gluconeogenic enzyme upregulated by 
the increased local cortisol levels, leading to the glucose intolerance observed in the 
dexamethasone-programmed marmoset offspring. 
 
In this thesis, we demonstrate the importance of renal 11β-HSD2 in the 
dexamethasone programming model in rats. More work will surely be needed to see 
if the decrease in 11β-HSD2 activity in the kidney is present in other species e.g. 
marmosets and most importantly, in low birth weight humans. Also, it has yet been 
determined if renal 11β-HSD2 is important in the pathogenesis of other models (e.g. 
maternal low-protein diet, uterine artery ligation), although there is emerging 
evidence that this may be a common programming target gene in the pathogenesis of 
hypertension in these other models of prenatal insults (Bertram C, 2001; Baserga M, 
2010). 
 
The finding that decreased renal 11β-HSD2 activity may be important in the 
pathogenesis of hypertension is well supported by physiology. Arthur Guyton and 
Richard Lifton have both argued convincingly from their work that for blood 
pressure to be elevated, the kidneys must somehow be involved by increasing the net 
sodium and water reabsorption (Guyton, 1991; Lifton 2001). With decreased renal 
11β-HSD2, which was shown to reside mainly in the distal tubules, corticosterone 
(the active glucocorticoid in rats), because of its high affinity for the 
mineralocorticoid receptor, might theoretically transactivate the mineralocorticoid 
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receptor leading to the molecular cascade ending in a higher net reabsorption of 
sodium and water, leading to hypertension as mentioned in the earlier chapters. 
 
It seems logical that the 11β-HSDs are key targets in programming (see Figure 1). 
By controlling tissue-specific glucocorticoid activation or inactivation, they allow 
local regulation of glucocorticoid action largely independent of the level of 
circulating cortisol, thus enabling the different tissues to fine-tune and adjust cortisol 
action independently through their varying levels of the 11β-HSDs. In our 
experiments, we found that only 11β-HSD2 mRNA expression was altered in the 
kidneys, and not in the other tissues examined – liver and adrenals. The mechanism 
of tissue-specific programming was not addressed in this thesis but it may involve 
perturbations of tissue specific transcriptional factors operative during critical 
window periods of organ development.  
 
In conclusion, it appears that glucocorticoid programming results in many 
coordinated metabolic changes in physiology. Many of these changes have already 
been shown to be mediated by changes glucocorticoid action- through altering levels 
of the glucocorticoid receptor, 11β-HSD1 and 11β-HSD2. We propose that these are 
important targets to explore in the other programming models and potentially 
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